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I. ANATOMY AND PATHOLOGY OF THE PITUITARY GLAND
The pituitary is a small neuro-endocrine organ with a diameter of only 1 centimetre, and 
a weight of about 0.5 gram. It is attached to the hypothalamus by the pituitary stalk and 
a portal system. The pituitary is composed of two morphologic and functional differ-
ent components: the anterior lobe (adenohypophysis) and the posterior lobe (neurohy-
pophysis). The adenohypophysis consists of five different endocrine cell types, identified 
by antibodies against pituitary hormones and capable of production and secretion of 
pituitary hormones:
1. Somatotroph cells. These cells are acidophilic and produce growth hormone (GH).
2. Lactotroph cells. These cells are acidophilic and produce prolactin.
3. Corticotroph cells. These cells are basophilic and produce adenocorticotrophic 
hormone (ACTH), pro-opiomelanocortin (POMC), melanocyte stimulating hormone 
(MSH) and endorphins.
4. Thyreotrophic cells. These cells are basophilic and produce thyrotrophin (TSH).
5. Gonadotrophic cells. These cells are basophilic and produce luteinising hormone 
(LH) and follicle-stimulating hormone (FSH).
The neurohypophisis produces the hormones oxytocin and arginine vasopressin (AVP). 
II. PITUITARY TUMORS
Different lesions may present as a mass within the sella turcica. In unselected autopsy 
series, the prevalence of pituitary tumors varies between 2 and 27%, with an average 
prevalence of 11% in a compilated series of 12.411 patients (1-3). The prevalence of 
adenomas > 1.0 centimetres in these series is less than 1% (1-4). Moreover, in series of CT 
or MR-imaging, in 10-20% of all patients small pituitary tumors can be detected (5;6). The 
differential diagnosis of a sellar mass is shown in Table 1 (adapted from Post et al (7) and 
Sam et al (8)). The differentiation between the various conditions causing a pituitary mass 
can sometimes be difficult, because these tumors may share similar clinical presentation 
and radiological features.
In patients operated for pituitary tumors, pituitary adenomas account for more than 
90% of the tumors (9). Of other causes, the most common diagnosis is Rathke’s cleft 
cyste (28%), craniopharyngioma (14%), metastatic carcinoma (12%), chordoma (11%) 
and meningioma (10%) (9). The proportion of patients with functioning, respectively, 
nonfunctioning adenomas among patients with pituitary adenomas, is dependent on 
the applied selection criteria. In series of patients operated for pituitary tumors, 25-50% 
of the adenomas is nonfunctioning, 50-75% is functioning. Off all pituitary adenomas, 







microadenomas, pituitary lesions turn out to be nonfunctioning adenomas in about 50%, 
the other 50% mainly being hormonal active adenomas (1;12). In contrast to microadeno-
mas, in patients with macroadenomas there is no equal distribution between functioning 
and nonfunctioning adenomas, nonfunctioning adenomas accounting for over 80% of 
all pituitary tumors (13-16). The reason for this higher prevalence of nonfunctioning 
pituitary adenomas is given by the fact that functioning adenomas are characterized by 
hormone excess, giving rise to clinical symptoms in an earlier phase of tumor growth 
and development. 
Table 1. Differential diagnosis of sellar masses






























III. NONFUNCTIONING PITUITARY ADENOMAS
Pituitary adenomas
Pituitary adenomas are non-metastasing neoplasms of the pituitary, composed of adeno-
hypophysal cells and lacking a true capsule (17;18). Pituitary adenomas are classified 
according to tumor size and to functionality. An adenoma with a diameter < 1 cm is 
defined as a microadenoma, an adenoma with a diameter > 1 cm as a macroadenoma. 
This differentiation between micro- and macroadenomas is clinically relevant, because, 
in contrast to microadenomas, macroadenomas may result in pituitary deficiencies and 
visual field defects. Pituitary tumors are staged according to the classification by Hardy 
and modified by Wilson (19). This classification is based on tumor diameter and local 
invasiveness (I-IV), and suprasellar/parasellar extension (A-E) (Figure 1).
Pituitary adenomas can be classified as either functioning or nonfunctioning according 
to their hormonal activity in vivo. Functioning adenomas are characterized by the over-
production of one, or in rare cases multiple, pituitary hormones. The hormonal activity 
of pituitary adenomas is usually a reflection of the underlying cytodifferentiation, which 
may consist of any of the cell types of the adenohypophysis. Nonfunctioning pituitary 
tumors are characterized by the absence of clinical and biochemical evidence of pituitary 
hormonal overproduction in vivo. Although from a clinical perspective nonfunctioning 
adenomas form a homogeneous group, from a pathological perspective they represent a 
heterogeneous group. By immunohistochemistry, the adenoma can be shown to consist 
of somatotroph, thyreotroph, lactotroph, gonadotroph or corticotroph cells, whereas ade-
nomas also may contain multiple hormonal cells (20). Because nonfunctioning adenomas 
Figure 1. Hardy-Wilson classification of pituitary tumors







lack clinical effects of hormone excess by definition, clinical nonfunctioning adenomas 
containing hormone producing cells are also referred to as silent pituitary adenomas. The 
most common silent adenomas are gonadotroph adenomas (20-22). These tumors contain 
immunoreactivity for α-subunits as well as β-subunits of LH and/or FSH. Adenomas that 
can not be classified according to immunohistochemistry are called null-cell adenomas. 
However, there is evidence that most cases of null-cell adenomas are gonadotroph ad-
enomas with low expression of immunoreactivity of gonadotroph cells (21;23). Some 
null-cell adenomas may be composed of pluripotental progenitor cells, capable of dif-
ferentiating to different hormone-producing cell lines (24). 
The rare pituitary adenomas that do metastasize are mainly functional in origin (21). 
A malign course in nonfunctioning pituitary adenomas is extremely rare (25), although 
local invasion is a frequent observed phenomenon in clinically nonfunctioning adenomas 
(26-28). 
Pathophysiology
Two different theories have been proposed to explain pituitary tumor-genesis. The first 
theory indicates hormonal stimulation as the initial event causing pituitary tumorgenesis. 
The second theory indicates an intrinsic pituitary defect as the initiating event. 
Almost all pituitary adenomas, both functioning and nonfunctioning, are monoclonal in 
origin (3;29), whereas polyclonal pituitary adenomas are extremely rare (18). In normal 
female tissue one of two x-chromosomes is inactivated. This event occurs randomly, 
leading to polyclonality in normal tissue (3). In female patients with pituitary adenomas, 
monoclonality of the tumor was proven by the loss of heterozygosity in tumor tissue (29).
This finding implies molecular alteration(s) as the underlying event for tumorgenesis and 
that pituitary adenomas arise from clonal expansion of a single mutated pituitary cell. 
Because of the monoclonality of the tumor, hypothalamus disorders, such as the overpro-
duction of hypothalamic, proliferative hormones, do not seem to play an important initial 
pathophysiologic role in pituitary adenomas. This is established by the lack of associated 
hyperplasia in pituitary tissue surrounding pituitary tumors (17;18). However, although a 
genetic modification seems to be the initiating step, hormones and/or growth factors may 
play a role in promoting subsequent cell proliferation. The molecular events leading to 
adenoma formation are incompletely understood (30). Molecular studies have revealed 
that most of the mutations present in other malignancies, are usually absent in clinical 
nonfunctioning adenomas (18). Several genes and molecular mechanisms have been 
proposed to be involved. Deletions in the region 13q14 have been identified in pituitary 
adenomas, pointing towards a possible tumor suppressor gene at this locus (18). Loss 
of expression of p16 is probably involved in the pathogenesis of adenomas, particularly 
in null cell adenomas (31). Pituitary tumor transforming gene (PTTG) is found to be 
overexpressed in a wide range of pituitary adenomas, although its role in tumorgenesis is 
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unclear (3). However, at present, the relationship between these molecular changes and 
clinical phenotype is unclear. 
Clinical presentation
The initial presentation of nonfunctioning pituitary adenomas depends largely on size 
and growth pattern of the tumor. In general, nonfunctioning microadenomas do not 
cause symptoms, because the tumor does not exceed the anatomical borders of the sella 
turcica, and pituitary function is preserved. However, even in about 15-20% of all patients 
with nonfunctioning macroadenomas, the tumor is discovered accidentally and not ac-
companied by clinical symptoms (32;33). The main presenting symptoms of nonfunction-
ing pituitary macroadenomas are headache, visual field defects and hypopituitarism due 
to mass effects of the tumor. Headache is present in about 40-50% of all patients (32;33) 
and can be caused by increased intracranial pressure and stretch of the dura mater (18). 
Visual disturbances are caused by compression of the optic chiasm. Typically, macroad-
enomas cause bitemporal field defects, explained by the anatomy of the visual pathways 
in the chiasm: the crossing inferonasal nerve fibres lie at the anterior part of the chiasm 
and are therefore compressed first. This causes the paradigmatic pattern of visual field 
defects: bitemporal defects of the upper quadrant. However, depending on the growth 
pattern of the tumor, there may exist asymmetry between the visual field defects of the 
two eyes. Visual field defects are present in the vast majority of all patients presenting 
with a pituitary macroadenoma (32;33).
Hypopituitarism is caused by three mechanisms: 1. compression of the pituitary stalk, 
which causes decreased availability of hypothalamic stimulatory hormones, 2. compres-
sion of functioning pituitary tissue, and 3. hypothalamic involvement of the pituitary 
tumor. In the majority of patients presenting with complaints of nonfunctioning pituitary 
macroadenomas, pituitary insufficiency is present to some degree (34-36). In addition to 
pituitary deficiencies, nonfunctioning macroadenomas can be accompanied by hyperpro-
lactinemia. The secretion and release of prolactin is inhibited by hypothalamic dopamine-
release. Pituitary tumors may disrupt dopamine release by compression of the pituitary 
stalk, and may therefore be accompanied by modest hyperprolactinemia. A prolactin 
level less than 100 µg/L is compatible with compression of the pituitary stalk (37;38). 
Other presenting signs of pituitary macroadenomas, though occurring infrequently, 
are cranial nerve dysfunction, diplopia and apoplexy. Cranial nerve dysfunction can be 
caused by infiltrating pituitary tumors. Apoplexy is a clinical syndrome resulting from 
acute haemorrhage or infarction of the pituitary tumor (39). In unselected patients with 









The treatment of choice for pituitary adenomas complicated by visual field defects is 
transsphenoidal surgery. Visual recovery has been demonstrated in the first days after 
surgical treatment (41;42) and is caused by decompression of the visual pathways, lead-
ing to a restoration of signal conduction. Visual field defects and visual acuity improve in 
more than 80% of the patients after transsphenoidal surgery (33;43-45), although visual 
field defects and visual acuity may worsen in a limited number of patients after surgery 
(46-49). 
The results of transsphenoidal surgery on pituitary function vary between different 
studies. Some studies report, to a variable degree, an improvement in pituitary func-
tion (45;50-53), whereas other studies could not demonstrate significant improvement 
in pituitary function (34;36;43) or even reported a decrease in pituitary function (35;54). 
Therefore, the aim of transsphenoidal surgery should be improvement of visual field 
defects, rather than improvement of pituitary function.
During long-term follow-up after transsphenoidal surgery, tumor recurrence is observed 
in 12-46% of the patients (43;44;55;56). The role of postoperative radiotherapy, in order 
to prevent tumor recurrence, is still under debate. Some centers provide postoperative 
radiotherapy in a selection of the patients to prevent tumor regrowth (35;36;56;57). None-
theless, even after postoperative radiotherapy, tumor recurrence was reported in 2-36% of 
the irradiated patients (36;44;55;56). The possible benefit of postoperative radiotherapy, 
i.e. a decrease in long-term growth rate of pituitary adenomas, has to be balanced against 
potential side effects of radiotherapy such as hypopituitarism (58-60) and secondary brain 
tumors (61). 
Mortality
Pituitary adenomas are accompanied by considerable morbidity. In macroadenomas mor-
bidity is caused by mass effects of the tumor leading to visual field defects, decreased 
visual acuity and pituitary insufficiency in the majority of patients (32;33). In acromegaly 
and Cushing’s disease, morbidity is caused by hormonal overproduction, in addition 
to tumor mass effect in cases of macroadenomas. In Cushing’s disease, cortisol excess 
causes central obesity, insulin resistance, hypertension and osteoporosis (62). Moreover, 
cortisol overproduction is associated with increased cardiovascular risk, continuing even 
after remission of the disease (63). In acromegaly exposure to growth hormone excess 
is associated with pathological conditions such as hypertension, cardial hypertrophy, 
diastolic dysfunction, insulin resistance, sleep apnea and ventilatory dysfunction (64;65). 
In patients with functioning pituitary adenomas (66;67), nonfunctioning pituitary adeno-
mas (68) as well as craniopharyngiomas (69), an increased standardized mortality ratio 
(SMR) have been reported. Moreover, in several studies, an increased SMR in patients 
with hypopituitarism has been reported (68;70-72). In the majority of studies the general 
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population was used as control group to assess mortality in patients with pituitary adeno-
mas. However, it is presently unknown to what extent the excess mortality is caused by 
pituitary tumors and their treatment in general, and to what extent (previous) by previous 
overexposure to cortisol or growth hormone. 
Quality of life assessment 
The assessment of Quality of Life (QoL) has increasingly become an important tool to 
assess the effects of disease and outcome of medical treatment. Quality of life refers to 
the patient’s perception of their physical, mental and social health. For numerous dis-
eases and treatment modalities quality of life has been investigated (73-80). In general, 
pituitary diseases are associated with impaired QoL (81). This can be explained by several 
factors. Macroadenomas are associated with different degrees of hypopituitarism, which 
require hormonal substitution. However, despite optimal endocrine replacement strate-
gies, normal endocrine function can not be perfectly restored by exogenous substitution. 
It is likely that this contributes to impaired QoL parameters in hypopituitarism. Moreover, 
growth hormone and ACTH producing adenomas induce irreversible effects through the 
syndromes of acromegaly (82) and Cushing’s disease (83), which persist despite long-
term cure of the disease. Finally, radiotherapy for pituitary tumors is associated with 
decreased QoL (82). 
IV. SCOPE OF THIS THESIS
In this thesis, the following important clinical aspects of the treatment of nonfunctioning 
pituitary macroadenomas will be addressed:
• The natural course of nonfunctioning pituitary macroadenoma
• Long-term outcome after transsphenoidal surgery
• Pattern of improvement in visual acuity after transsphenoidal surgery
• Mortality in patients with pituitary adenomas 
• Quality of Life assessment
The natural course of nonfunctioning pituitary macroadenoma
Because the majority of patients with NFMA are operated, the natural course of NFMA is 
largely unknown. In chapter 2 we present the outcome of a study, designed to estimate 
the natural course of NFMA in non-operated patients. Studies on the natural course of 
nonfunctioning macroadenomas are important, not only because they fill a gap in common 
knowledge. Until now, the majority of patients with a nonfunctioning macroadenoma will 







more detailed knowledge of the natural course of nonfunctioning pituitary macroadeno-
mas may select patients in whom a conservative approach is more appropriate. 
Long-term outcome after transsphenoidal surgery
Transsphenoidal surgery is the golden standard in the treatment of nonfunctioning pi-
tuitary macroadenomas with visual field defects. However, the role of postoperative ra-
diotherapy is still under debate. Prospective trials evaluating the effect of postoperative 
radiotherapy on regrowth rates of NFMA have not been published. Only 2 studies have 
been published in consecutive NFMA patients with a wait and see policy after transsphe-
noidal surgery (32;43). However, these reports do not propose a wait-and-see policy for 
all NFMA patients.
In chapter 3 we present the results of a treatment strategy in which postoperative 
radiotherapy was not applied in consecutive patients after transsphenoidal surgery. The 
main question was whether a treatment strategy without postoperative radiotherapy may 
lead to good tumor control, without adversely affecting patient’s outcome. A wait-and-see 
policy after transsphenoidal surgery would have the advantage to postpone the possible 
side effects of radiotherapy in patients with tumor recurrence for several years. 
Pattern of improvement in visual acuity after transsphenoidal surgery
One of the main goals of surgical treatment in nonfunctioning macroadenomas, is the 
restoration of visual function. The process of recovery of visual field defects starts im-
mediately after surgery and can already be documented on the second postoperative day 
(41). This process of recovery is probably due to restoration of the velocity of conduction 
in the optic nerves. However, improvement of visual field defects appears to continue 
even years after initial surgical treatment (42;85). This second, slow phase of recovery 
may reflect restoration of axonal transport and remyelination. 
The process of gradual visual improvement, has only been studied for visual field de-
fects, not for visual acuity (42). In chapter 4 we present data on the pattern of recovery 
of visual acuity until one year after transsphenoidal surgery for nonfunctioning pituitary 
macroadenoma. 
Mortality in patients with pituitary adenomas 
An increased SMR has been reported in both hypopituitarism and pituitary tumors (68). 
However, it is presently unknown to what extent the excess mortality is caused by pitu-
itary tumors and their treatment in general, and to what extent by (previous) exposure to 
cortisol or growth hormone overproduction. 
In chapter 5 we describe a single centre study to assess mortality ratios during long 
term follow up after transsphenoidal surgery in patients with nonfunctioning pituitary 
macroadenomas and Cushing’s disease. To answer to the question to which extent previ-
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ous exposure to hormonal overproduction per se is associated with increased mortality, 
we compared mortality in patients operated for Cushing’s disease to mortality in patients 
operated for nonfunctioning pituitary macroadenomas. 
Quality of Life assessment
Although quality of life has been investigated in patients with functioning pituitary tumors 
(83;86), no studies on QoL in patients treated for nonfunctioning adenomas, compared 
to healthy controls, have been published. Most studies on QoL in pituitary diseases were 
not focussed on nonfunctioning tumors, but included heterogeneous groups, consisting 
of both functioning and nonfunctioning pituitary tumors (87-90). In chapter 6 we present 
the results of a quality of life assessment in adult patients treated by transsphenoidal sur-
gery for nonfunctioning macroadenomas. In chapter 7 we present the same assessment 
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Objective. The natural history of nonfunctioning pituitary macroadenomas (NFMA) has 
not been fully elucidated. Therefore, we evaluated pituitary function, visual fields and 
tumor size during long-term follow-up of non-operated patients with NFMA. 
Design. Follow-up study
Patients. Twenty-eight patients (age 55 ± 3 years) with NFMA, not operated after initial 
diagnosis, were included.
Results. Initial presentation was pituitary insufficiency in 44%, visual field defects in 
14%, apoplexy in 14%, and chronic headache in 7% of the patients. The duration of fol-
low-up was 85 ± 13 months. Radiological evidence of tumor growth was observed in 14 
of 28 patients (50%) after duration of follow-up of 118 ± 24 months. Six patients (21%) 
were operated, because tumor growth was accompanied by visual field defects. Visual 
impairments improved in all cases after transsphenoidal surgery. Spontaneous reduc-
tion in tumor volume was observed in 8 patients (29%). No independent predictors for 
increase or decrease in tumor volume could be found by regression analysis.
Conclusion. Observation alone is a safe alternative for transsphenoidal surgery in se-
lected NFMA patients, without the risk of irreversibly compromising visual function.
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INTRODUCTION
Nonfunctioning pituitary macroadenomas (NFMA) are the most prevalent pituitary 
macroadenomas (1,2). Although NFMA’s are benign in origin, mass effects may lead to 
serious clinical symptoms such as visual impairments, chronic headache and pituitary 
insufficiency. At the time of initial diagnosis, visual field defects are detected in 60-80% 
of NFMA patients (3-5). Transsphenoidal surgery is the treatment of choice in NFMA 
patients with visual field defects. The main aim of surgical treatment is improvement of 
visual function, which is achieved in over 80% of cases (3,6). Studies on the effect of 
surgery in NFMA on pituitary function show conflicting results. Some studies report, to 
a variable degree, an improvement in pituitary function (4,7-11), whereas others could 
not demonstrate significant improvement in pituitary function, or even showed decreased 
pituitary function after transsphenoidal surgery (3,5,12,13). Transsphenoidal surgery leads 
to long-term tumor control in ~ 80% of patients (3,14-16), and, in selected series, in even 
more than 90% of the patients (15,17). 
The natural course of NFMA is largely unknown, because the majority of patients with 
NFMA are operated. The natural course of pituitary incidentalomas was reported in 5 
previous reports (1,18-21). In 4 of these reports, data on the natural course of NFMA were 
reported (1,18,19,21). The fifth study described the combined data of both nonfunction-
ing microadenomas and macroadenomas, not permitting a conclusion with respect to the 
natural course of NFMA per se (20). Those studies, with a follow-up period ranging from 
22 to 73 months, show an increase in tumor size ranging from 25 to 50% of all patients 
with NFMA. The natural course of NFMA presenting for other reasons than the presence 
of an incidentaloma is unclear.
The main indication for surgery in patients with NFMA in our hospital is the presence of 
visual impairment. In the absence of visual field defects, the initial therapeutic approach 
is to evaluate tumor growth and visual function with regular intervals. In patients with 
only minimal visual field defects surgery is deferred. The aim of the present study was to 
evaluate changes in pituitary function, visual function and tumor size during long-term 
follow-up of these non-operated patients with NFMA. 
PATIENTS AND METHODS
Between 1981 and 2005, 232 consecutive patients were diagnosed with NFMA at the 
Leiden Universitary Medical Center. Patients were included in this study based on the 
following criteria:
1. Macroadenoma on MR imaging 







3. A prolactin level below 100 µg/L to exclude possible prolactinomas (22,23)
4. Expectative approach after initial diagnosis 
5. At least two sequential MRI’s to evaluate tumor-growth. 
The vast majority of the patients (n=195), was operated after diagnosis. In 37 patients 
initially an expectative approach was undertaken after diagnosis. Nine of these patients 
were not eligible for the present study, for the following reasons: follow-up by CT scan 
only (n=5), lost to follow-up (n=1), no follow-up by MRI because of very high age and 
the absence of visual field defects (n=2), follow-up period shorter than one year (n=1). 
Consequently, a total of 28 patients was included in this study. The duration of follow-up 
was defined as the interval between the first and the last MRI-scan. Because the study 
was designed to assess the natural course of NFMA’s, in case of an operation for NFMA, 
the last MRI before surgery was assigned as the end of follow-up. 
An experienced endocrinologist saw each patient, at least twice a year. Growth hor-
mone (GH) deficiency was defined as an IGF-1 level below the reference range for age 
and sex (24), and/or an insufficient rise in GH levels (absolute value < 3 µg/L) after 
stimulation during an insulin tolerance test (ITT). Before 1992, serum GH was measured 
by RIA (Biolab/serono, Coinsins, Switzerland). The RIA was calibrated against WHO-
IRP 66/21, with an interassay variation coefficient below 5%. From 1993 onwards GH 
was measured by immunofluorometric assay (Wallac, Turku, Finland), calibrated against 
WHO-IRP 80-505, with an interassay variation coefficient of 1.6-8.4% between 0.1 and 15 
µg/L. IGF-1 determination was performed by RIA available since 1985 (INCSTAR Corp., 
Stillwater, MN), with an interassay variation less than 11%. ACTH deficiency was defined 
as a basal cortisol level at 8.00 A.M. of < 0.12 µmol/l and/or an insufficient increase in 
cortisol levels (absolute value < 0.55 µmol/ l) after an insulin tolerance test (ITT: nadir 
glucose < 2.2 nmol/L). In two patients, an ITT was contraindicated and a corticotrophin 
releasing hormone (CRH) stimulation test was performed, using human CRH, in which 
we used the same cut-off levels for cortisol concentrations like in the ITT. Cortisol was 
measured with three different immunoassays over time. Until 1986 cortisol was measured 
by in house RIA with an interassay coefficient of variation of 10%. Between 1986 and 
1994 a fluorescence energy-transfer immunoassay Syva Advance (Syva Company, Palo 
Alto, CA) was used, with an interassay variation coefficient of 3.6 to 6.1%. From 1994 
cortisol was measured by fluorescence polarisation assay on a TDx (Abbott, Abbott Park, 
Ill). The interassay variation coefficient is 5-6% above 0.5 µmol/l and amounts to 12% 
under 0.20 µmol/l. In addition, the biannual evaluation consisted of measurement of free 
T
4,
 LH/FSH (all patients), estradiol (premenopausal female patients), and testosterone 
(male patients) concentrations. Prolactin was measured with a sensitive time-resolved 
fluoro-immunoassay (Wallac, Turku, Finland), calibrated against WHO 3rd International 
Standard for Prolactin 84/500. The interassay coefficient of variation was 3.4 to 6.2% in 
the assay range from 3.0 to 80 µg/L. 
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The evaluation of visual function was done by an ophthalmologist, and included vi-
sual acuity, pupillary fundus and visual fields. Visual fields were assessed by Humphrey 
perimetry in all patients. Goldman perimetry was used as an additional tool to assess 
peripheral visual field defects. Ophtalmologic assessment was performed at baseline, 
after six months and subsequently at yearly intervals. Visual field defects were classified 
as minimal if there was a small defect in only one eye in only one quadrant.
Repeat MRI was performed within one year after the initial diagnosis. If no growth was 
observed, subsequent MRI scanning was performed every second year.
The follow-up of the patients was part of regular medical care. The approaches de-
scribed in this paper did not involve any randomization or any experimental intervention. 
According to Dutch law, each patient has to be fully informed on the pros and contras of 
each treatment strategy, and each patient can only be treated after giving oral informed 
consent. 
Assessment of radiological imaging
Two observers evaluated all MRI scans, independently of each other. Tumor volume was 
assessed by measuring the largest diameter of the tumor in three directions. The vertical 
diameter (V) was measured on sagittal T1 weighted and coronal T1 weighted scans, 
anteroposterior (AP) diameter on coronal T1 weighted scans and transversal diameter (T) 
on T1 weighed sagittal scans. 
Imaging was performed on MR scanners with different field strengths, ranging from 
0.5 Tesla to 1.5 Tesla. Imaging parameters included the following: A field of view (FOV) 
of 190 mm2 and a matrix size of 256 x 512 mm, yielding an in-plane spatial resolution of 
0.74 x 0.37 mm (scan duration was increased at lower field strengths in order to maintain 
sufficient resolution). Tumor volume assessment was not performed by the same MRI-
scanner in each patient, because the higher strength MRI’s were not available during the 
initial part of the observation period of the present study. 
Tumor growth was defined as an increase in tumor size on MRI of more than one mil-
limeter in any direction, independent of the development of visual field defects. Tumor 
volume was assessed as the volume of a rotating ellipsoid, with the following formula: 
π/6 (VxAPxT) (25).
Statistics
Binary logistic regression was performed to assess predictors for increase or decrease in 
tumor growth. All data are expressed as mean ± standard error, unless otherwise men-








Patient characteristics (Table 1)
Twenty-eight patients were included. Mean age at presentation was 55 ± 3.3 years. The 
duration of follow-up was 85 months ± 13 months. Initial presentations were pituitary in-
sufficiency in 44%, visual field defects in 14%, apoplexy in 14%, and chronic headache in 
7% of the patients. In only 6 patients (21%) the macroadenoma was an incidental finding. 
Radiological imaging revealed a macroadenoma in all cases, with suprasellar extension in 
61% and/or lateral/infrasellar extension in 44% of cases. A large number of patients had 
pituitary insufficiency (71%) of one (32%) or more axis (39%). 
Visual field defects were present in 13 patients at initial presentation. In 6 of these 
patients the defects were classified as minimal. Visual acuity was normal in 6 of 7 patients 
with more than minimal visual field defects. 
Table 1. Patient characteristics at initial presentation (n = 28)
Male/Female 15/13








Intact function of anterior pituitary gland 29%
Single pituitary deficiency 32%
Multiple pituitary deficiencies 25%
Panhypopituitarism 14%
Prolactin (µg/L) in male patients (median + range) 13, range 0.3-50.6 
Prolactin (µg/L) in female patients (median + range) 16, range -4.2 to 1.17
 IGF-1 SD score (median + range) -0.5, range -4.2 to 1.2
MRI characteristics




No visual field defects 54%
Minimal visual field defects 21%
Bitemporal visual field defects 25%
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Treatment strategy
Fifteen of the 28 patients where not operated because they did not have any visual field 
defects. In 6 other patients a conservative approach was chosen, because they had only 
minimal visual field defects. Seven patients were not operated despite visual field defects 
for the following reasons. The pattern of the visual field defects was not compatible with 
the diagnosis of chiasm compression, and there was a more likely ophthalmologic expla-
nation of the defects (N=2). In 2 other patients, one of which had decreased visual acuity, 
surgical treatment was contraindicated because of high age, and serious co-morbidity. 
Finally, in 3 patients with visual field defects and pituitary apoplexy an initial expectative 
approach was chosen. In all subjects a wait-and-see approach was chosen with careful 
follow-up of the visual function.
Radiological follow-up
All 28 patients had at least two MRI scans, with a mean interval between the first and 
the last MRI of 85 ± 13 months. Radiological evidence of tumor growth was observed in 
14 of 28 patients (50%), after a duration of follow-up of 118 ± 24 months (Table 2). In 
these patients, the mean tumor volume increased from 3489 mm3 ± 538 mm3 to 5318 mm3 
± 820 mm3. The mean increase in tumor size, estimated by the growth in the diameter 
with the largest growth, was 0.6 mm/year. Growth velocity, expressed in mm3, was 236 
mm3/year. If we exclude the 4 patients with apoplexy at initial presentation, because in 
Table 2. Characteristics of patients with tumor enlargement (n=14)
Age at diagnosis Female/male Follow-up (months) Tumor volume at diagnosis 
(mm3)
Tumor volume end follow-up 
(mm3)
40 F 30 3050 3577
35 F 36 1406 1631
29 F 48 2276 4382
77 F 81 1422 2454
66 F 144 4351 4853
40 F 240 5292 6351
41 M 24 761 1435
42 M 24 2197 2504
53 M 36 4445 6975
75 M 60 6778 8420
74 M 72 4710 6463
72 M 180 6328 10525
64 M 204 4832 10826
58 M 264 1004 4059







these cases subsequent tumor enlargement is less probable, an increase in tumor volume 
was observed in 58% of the remaining patients during prolonged follow-up.
Remarkably, reduction in tumor volume was observed in 8 patients (29%). In those 8 
patients tumor volume decreased from 3040 mm3 ± 912 mm3 to 1434 mm3 ± 443 mm3. Two 
of those 8 patients initially presented with pituitary apoplexy. 
In the remaining 6 patients (mean tumor volume 5286 mm3 ± 3061 mm3) no change in 
tumor volume could be detected by MRI. In one patient, despite a follow-up period of 
216 months, no tumor growth could be observed.
Binary logistic regression was performed in a model including increase and decrease 
in tumor volume as dependent variable and age, gender, tumor volume, tumor exten-
sion, hypopituitarism, prolactin levels and follow-up duration as independent variables. 
No independent predictors for increase or decrease in tumor volume could be found by 
regression analysis.
Ophthalmologic follow-up
In 9 of the 14 patients, tumor growth on MRI was associated with increased defects of 
visual fields. In 7 of those 9 patients the visual field defects were likely caused by tumor 
mass effect. In the two other patients, one with glaucoma and one with uveitis, the 
predominant defects were not in the upper temporal quadrant. In 4 patients with tumor 
growth no visual field defects could be detected. In one patient, who had only minimal 
visual field defects, there was no increase in visual field defects. In 2 of the 8 patients 
with a decrease in tumor volume on MRI, an improvement of visual defects could be 
observed. 
Four patients had apoplexy as presenting symptom, accompanied by visual field de-
fects in 3 of them. In all these three patients visual fields normalized spontaneously 
within three months.
Endocrine follow-up
In 3 of the 14 patients with growing tumors on MRI, an increase in pituitary deficiencies 
was observed, whereas in the other 11 patients pituitary functions remained stable. In 
only one of the 8 patients with a decrease in tumor size, there was an improvement of 
pituitary function. 
In 1 of the 4 patients with pituitary apoplexy, initial pituitary deficiencies were present 
in 3 of 4 axis, including ACTH deficiency. In this patient pituitary deficiencies resolved 
within three months. The other 3 patients presented with apoplexy had normal pituitary 
function
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Long-term outcome (Figure 1)
The mean follow-up period was 85 ± 13 months. At the end of follow-up, in 14 patients 
without signs of tumor growth on MRI, there was still no indication for surgery. Six 
patients were operated, because tumor growth was accompanied by visual field defects. 
After transsphenoidal surgery, visual field defects improved in these 6 patients. In 5 other 
patients with tumor growth, the conservative approach was continued because of normal 
visual fields (n=4), or, stable, minimal visual field defects (n=1). Three patients with 
tumor growth and visual field defects were not operated, because of non-compatibility 
of the defects with compression of the optic chiasm by NFMA (n=2), or high age and 
associated co-morbidity (n=1). In the last patient visual field defects were accompanied 
by a slight decrease in visual acuity. 
DISCUSSION
In this study we evaluated the natural course of NFMA. In 28 NFMA patients, with a mean 
follow-up period of more than 7 years, tumor growth was observed in 14 patients (50%). 
Figure 1. Long-term outcome after expectative approach for NFMA
Figure 2.1: Long-term outcome after expectative approach for NFMA 
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Improvement in visual field 
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In 7 of these patients, tumor growth was accompanied by (increased) visual field defects, 
likely to be caused by mass effects of the tumor. Surgical intervention was performed 
in only 21% (n=6) of all patients, and improved visual fields in all cases. Remarkably, a 
spontaneous decrease in tumor volume was observed in 29% of the patients during long-
term follow-up. Thus, in the absence of visual impairments, observation alone is a safe 
alternative for surgery in selected patients with NFMA, since surgery can ultimately be 
withheld in the majority of these patients, without compromising visual field defects. 
To date, only 4 studies reported the natural course of NFMA, discovered as incidentalo-
mas, comprising a total of 41 patients (1,18,19,21), whereas an additional study reported 
the natural course of a combined series of both nonfunctioning micro- and macroad-
enomas (20). Those studies, summarized in Table 3, with a follow-up period of 22-73 
months, report an increase in tumor size in about 25-50% of the patients However, several 
aspects of the design of the present study were different from those previous studies. We 
included all NFMA patients, in whom surgery was not performed for any reason. In con-
trast to these previous studies, an incidentaloma was the initial finding in only a minority 
of our patients. Therefore, the characteristics of our study population are different, with 
a higher prevalence of pituitary insufficiency and visual field defects than those in the 
previous studies (1,19). 
Previous studies also showed that tumor growth does not invariable lead to visual 
field defects (1,18,20,21). In our series tumor growth (n=14) was accompanied by visual 
field defects in only 9 patients. Moreover, in only 7 of these patients the pattern was 
compatible with tumor mass effect. In all patients operated for tumor growth and visual 
field defects, these defects improved or normalized. These data suggest that in case of 
the development of visual field defects in the course of NFMA, surgical outcome still 
is favourable with respect to visual field defects. These results are in accordance with 
observations in surgical series, which documented improvement of visual field defects in 
80% of NFMA patients after transsphenoidal surgery (3,6).
In pituitary microadenomas in general, tumor growth is observed in only a minor-
ity of the patients, in contrast to NFMA. Moreover, in microadenomas, the chance of 
Table 3. The natural course of tumor volume in nonfunctioning pituitary macroadenomas




Feldkamp et al. (1) N = 19 32 months N = 5 N = 1
Donovan et al. (18) N = 16 73 months N = 4 N = 0
Reincke et al. (19) N = 7 22 months N = 2 N = 0
Sanno et al. (20) N = 115 a 51 months N = 23 N = 11
Arita et al. (21) N = 42 62 months N = 21 N = 1
Present series N = 28 85 months N = 14 N = 8
a Consisting of both nonfunctioning pituitary microadenomas and macroadenomas
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tumor growth seems to be almost outweighed by the change of a decrease in tumor 
size (1,20). In patients with NFMA the tumor already has demonstrated a propensity for 
growth. Nonetheless, after a mean follow-up period of 85 months no tumor growth could 
be detected in this study in 50% of cases. However, at initial presentation, the rate of 
tumor growth cannot be predicted in individual patients. In our study, no independent 
predictors for increase or decrease in tumor volume could be found by binary logistic 
regression.
In patients with NFMA, it is a reasonable approach to repeat MR imaging one year 
after initial diagnosis, in order to make a first estimation of tumor growth. In our study, 
in patients with tumor growth, the mean increase in diameter was only 0.6 mm/year, 
which is below the detection limit of MRI. These data suggest that, for further follow-up, 
an approach with a repeat MRI every second year is safe and optimal for detection of 
possible tumor growth. 
Diagnostic accuracy might be a limitation of this study, because, in strict sense, pituitary 
adenoma is a histopathological diagnosis and a number of other sellar lesions may mimic 
pituitary adenomas, such as germinomas, craniopharyngiomas, meningiomas, sarcoidosis 
and lymphocytic infiltration (26). However, there are, in addition to the absence of hor-
mone overproduction, arguments that in our series the vast majority of the lesions consist 
of NFMA. In autopsy series pituitary lesions turn out to be nonfunctioning adenomas 
in about 50%, the other 50% mainly being hormonal active adenomas (2,27). Moreover, 
in the vast majority of patients, MRI can with adequate accuracy differentiate between 
pituitary adenomas and craniopharyngiomas (28,29), and between pituitary adenoma and 
pituitary hypertrophy (30). 
The possibility of pituitary apoplexy must be taken into account in the discussion of 
surgical versus conservative management of nonfunctioning macroadenomas. Apoplexy 
is a clinical syndrome resulting from acute haemorrhage or infarction of the pituitary 
tumor (31). In unselected patients with NFMA, apoplexy is the presenting sign in 15-25% 
of the patients (13,32). Only a minority of patients presenting with apoplexy were known 
to harbour a pituitary tumor (33). In contrast, the incidence of apoplexy in patients 
already known to have a pituitary tumor is estimated to be less than 1%/year (20). In 
patients with macroadenomas the incidence of apoplexy is probably higher (21). The 
occurrence of pituitary apoplexy has been described following pituitary function tests 
(34), coronary artery bypass surgery (33,35), cholecystectomy (36), head trauma (37) and 
vaginal delivery (38). Moreover, apoplexy has been associated with hypertension (33) 
and anticoagulant therapy (38). The majority of patients with pituitary apoplexy present 
with ACTH-deficiency (33), establishing the potential life threatening condition of the 
clinical syndrome. In the present series 4 patients presented with pituitary apoplexy. In 
3 of these cases apoplexy was accompanied by visual field defects, and one patient had 







the pituitary deficiencies resolved within three months. Although the optimal treatment 
for NFMA patients presenting with pituitary apoplexy is still a matter of debate (39-41), 
surgical intervention is indicated in patients presenting with total or near-total visual 
loss. After transsphenoidal surgery visual impairment and ocular paresis resolves in the 
majority of cases (39-41). However, conservative management with careful follow-up, 
seems appropriate in selected patients without, or with only mild neuro-ophtalmic signs, 
without adversely affecting patient outcomes (33,39). 
In conclusion, our series with non-operated NFMA patients report an increase in tu-
mor size in 50% of all patients during long-term follow-up, accompanied by visual field 
defects in 50% of these cases. In patients with an increase in tumor size and visual field 
defects, surgical treatment resolved the visuals field defects. No independent predictors 
for tumor growth were found by logistic regression. Based on these data, we propose 
a conservative approach in selected patients with NFMA without visual field defects. In 
these patients, this is a safe alternative for transsphenoidal surgery, without the risk of 
irreversibly compromising visual field defects.
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Objective: Transsphenoidal surgery is the treatment of choice for nonfunctioning pituitary 
macroadenomas (NFMA). In this study we evaluated the long-term effects of a treatment 
strategy in which postoperative radiotherapy was not routinely applied to patients with 
NFMA.
Design: Retrospective follow-up study 
Patients: We included 109 consecutive patients (age 56 ± 13 years) operated for NFMA 
between 1992 and 2004.
Results: Radiological imaging revealed a macroadenoma in all patients, with suprasellar 
extension in 96% and parasellar/infrasellar extension in 36% of cases. Visual field defects 
were present in 87% of the patients and improved in 84% of these patients after surgery. 
Only six patients received postoperative radiotherapy. Ten patients died during the fol-
low-up period. Ninety-seven patients could be assessed for tumor regrowth or tumor 
recurrence after a mean follow-up period of 6.0 ± 3.7 years. In nine patients there was 
evidence for tumor regrowth, and in one patient tumor recurrence was observed. The 
mean time to tumor growth/recurrence after initial therapy was 6.9 (range 3-12) years. 
Follow-up duration was found to be an independent predictor for tumor regrowth.
Conclusion: Transsphenoidal surgery without postoperative radiotherapy is an effective 
and safe treatment strategy for NFMA, without evidence for tumor regrowth in 90% of all 
patients, at least for the duration of follow-up presented in this study. Additional studies 
are required to exclude higher regrowth and recurrence rates during prolongation of the 
duration of follow up.
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INTRODUCTION
Nonfunctioning pituitary macroadenomas (NFMA) are the most prevalent macroadeno-
mas (1;2). The main presenting symptoms of NFMA are visual field defects and hypopi-
tuitarism due to mass effects. Transsphenoidal surgery is the treatment of choice because 
medical treatment in general is not effective in reducing the size of NFMA. However, 
during long-term follow-up after transsphenoidal surgery, there is tumor growth in 12-
46% of the patients (3-6). Therefore, some centers provide postoperative radiotherapy in 
a selection of the patients to prevent tumor regrowth (6-9). Nonetheless, even after post-
operative radiotherapy, tumor regrowth was reported in 2-36% of the radiated patients 
(4-6;9). In addition, radiotherapy induces a higher incidence of hypopituitarism during 
long-term follow-up (10-12) and is associated with rare complications such as secondary 
brain tumors (13). Therefore, a restrictive indication for postoperative radiotherapy seems 
appropriate.
Prospective trials evaluating the effect of postoperative radiotherapy on regrowth rates 
of NFMA have not been published. Retrospective studies, involving homogeneous cohorts 
of transsphenoidal operated NFMA with a long follow-up period, are scarce (3-6;9;14;15). 
Only two studies have been published in consecutive NFMA patients with a wait and 
see policy after transsphenoidal surgery. These studies, comprising of 71 and 51 patients 
respectively, report tumor growth in 21 and 26% during long term follow-up (3;15). How-
ever, these reports do not propose a wait-and-see policy for all NFMA patients. The aim 
of the present study was to evaluate the long-term effects of a wait-and-see policy after 
transsphenoidal surgery for NFMA on tumor recurrence rates in an unselected, homoge-
neous, single center cohort of 109 consecutive patients operated for NFMA. Postoperative 
radiotherapy was applied only in six of the 109 patients.
PATIENTS AND METHODS
Patient selection
Between 1992 and 2004, 109 consecutive patients were treated by transsphenoidal surgery 
for NFMA (diameter > 1 cm) at the Leiden University Medical Center. All operations were 
performed by one of two neurosurgeons. For complete assessment of the patients, we re-
viewed the patient records of all departments involved in the treatment of NFMA. Patients 
were assessed at presentation prior to surgery, within the first 2 months after surgery, and 
subsequently every 6 months during prolonged follow-up. Clinical characteristics, visual 
field defects, pituitary function and MRI images were assessed. Pre-and post-surgical data 
were available for all 109 patients. In 97 patients at least two postoperative MRI-scans 







patients died during the follow-up period, one post-operatively. The duration of follow 
up in each patient was determined by the interval between the date of transsphenoidal 
surgery and the date of the last MRI scan. In six patients postoperative radiotherapy 
was applied. Patients receiving prophylactic radiotherapy were treated with conventional 
external radiotherapy. All these patients received 46 Gy. Three patients were treated with 
220 degree arc therapy and three patients with three-field arrangement, that included left 
lateral, right lateral and anterior portals.
NFMA was diagnosed if there was neither clinical nor biochemical evidence of hor-
monal overproduction and histopathological evaluation revealed an adenoma. Histologi-
cal examination confirmed the diagnosis of pituitary adenoma in all, except five patients, 
in whom appropriate histological assessment was precluded due to necrosis of the tumor. 
Adenomas were classified according to immunohistochemistry as either negative or posi-
tive for one or more hormone and/or their subunits.
Definitions
Growth hormone (GH) deficiency was defined as an IGF-1 level below the reference 
range for age and sex (16) and/or an insufficient rise in GH levels (absolute value < 3 
µg/L) after stimulation during an insulin tolerance test. Prior studies demonstrated that 
patients with multiple pituitary hormone deficiencies, including two or more pituitary 
hormone deficiencies other than GH deficiency, had a likelihood of approximately 95% 
of harbouring severe GH deficiency (16-18). Based on these data, we classified patients in 
whom GH-stimulation test data were lacking but who were deficient in 3 other pituitary 
axes as being GH deficient. When secondary amenorrhoea was present for more than 1 
year premenopausal women were defined as LH/FSH deficient. Postmenopausal women 
were defined as LH/FSH deficient, when gonadotrophin levels were below the normal 
post-menopausal range (LH < 10 U/l, FSH < 30 U/l). In men, LH/FSH deficiency was 
defined, as a testosterone level below the reference range (8.0 nmol/L). TSH deficiency 
was defined as a total or free T4 level below the reference range. ACTH deficiency was 
defined as a basal cortisol level at 8.00 A.M. of < 0.12 µmol/l and/or an insufficient 
increase in cortisol levels (absolute value < 0.55 µmol/ l) after a corticotrophin releasing 
hormone stimulation test or insulin tolerance test. Hypopituitarism was defined by the 
presence of one or more pituitary hormone deficiencies. Diabetes insipidus was defined 
as polyuria not reacting to fluid restriction but reacting to administration of vasopressin. 
The pituitary tumors were assessed by MRI scanning. Tumor extension was classified 
as suprasellar, parasellar/infrasellar, or combined suprasellar and parasellar/infrasellar 
extension. MRI imaging was performed in all patients within 6 months following trans-
sphenoidal surgery, for the second time one year later, and subsequently with increasing 
intervals. Patients were classified according to the post-operative MRI as having residual 
tumor or not having residual tumor. Patients with uncertain MRI diagnosis with respect to 
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tumor residue were classified as having residual tumor (15). Tumor regrowth was defined 
as an increase in size of residual tumor. Recurrence was defined as appearance of tumor 
mass in a patient without residual tumor mass on postoperative MRI. 
Ophthalmological evaluation included assessment of visual acuity and visual fields, 
performed by a Humphrey or Goldmann perimeter before and a few weeks after surgery. 
Patients who had persistent visual field deficits after surgery or noticed visual disturbances 
any time during prolonged follow up were re-assessed by the ophthalmologist. 
Statistical analysis
The unpaired t-test was used for continuous variables. The χ2 test and the McNemar test 
were used for categorical data. Binary logistic regression was performed to explore pos-
sible determinants of tumor growth. Tumor regrowth-free survival was analyzed with the 
method of Kaplan and Meier. SPSS software version 12.0 (SPSS Inc., Chicago, IL, USA) 
was used. A P-value of < 0.05 was considered statistically significant. 
Table 1. Patient characteristics before surgery
Number of patients 109
Mean age (years) 56 ± 13
Male 61/109 (56%)
Clinical presentation
Visual field defects 90/104 (87%)
Headache 41/105 (39%)
Cranial nerve deficit 8/109 (7%)
Apoplexia 8/101 (8%)
Pituitary deficiencies
GH deficiency 58/75 (77%)
LH/FSH deficiency 77/103 (75%)
ACTH deficiency 53/101 (53%)
TSH deficiency 45/106 (43%)
Panhypopituitarism 32/109 (29%)
Radiology
Suprasellar extension 105/109 (96%)
Parasellar/infrasellar extension 39/109 (36%)
Immunohistochemistry
Positive immunostaining 68/104 (65%)
Silent gonadotropinoma 41/104 (39%)
Silent corticotropinoma 11/104 (11%)








Preoperative patient characteristics (Table 1)
The most prevalent presenting symptoms were visual field defects (87%) and headache 
(39%). NFMA presented as apoplexy in 8 cases. Radiological imaging by MRI revealed a 
macroadenoma in all patients, with suprasellar extension in 96% and parasellar/infrasel-
lar extension in 36% of cases. Hypopituitarism was present in 80% of all patients and 
panhypopituitarism in 29%. 
Surgical treatment 
All patients were treated by transsphenoidal surgery. One patient died of subarachnoidal 
bleeding two days after surgery, resulting in a perioperative mortality rate of 0.9%. Repeat 
surgery within 6 months after initial treatment was performed in 6% of cases (n=7), for 
a large residual tumor mass (n=4), persisting liquor leakage (n=2) and profuse bleeding 
(n=1). Repeat surgery was performed by transcranial approach, except in the two patients 
with leakage of cerebrospinal fluid.
Transsphenoidal surgery was followed by radiotherapy in six patients. The decision 
to apply prophylactic radiotherapy was based on the presence of a large residual tumor 
(n=3) or a residual tumor with strongly positive immunostaining for ACTH (n=3). 
Immunohistochemistry could be assessed in 95% of cases and was positive in 65%. Off 
all cases, 39% harboured a silent gonadotrophic adenoma, 11% a silent corticotrophic 
adenoma, and 9% was immunoreactive for multiple hormones.
Post-operative MRI revealed residual tumor in 73% of all cases. 
Post-operative evaluation: visual field defects and pituitary deficiencies (Table 2)
Visual field deficits improved in 84% of cases after surgery (complete recovery 21%; 
partial recovery 63%). Visual field defects stabilized in 13% and deteriorated in only three 
patients after surgery. 
After surgical treatment 90% of the patients were LH/FSH deficient, 83% GH defi-
cient, 60% ACTH deficient and 57% TSH deficient. Hypopituitarism was present in 95% 
of cases and panhypopituitarism in 44%. When compared with the pre-surgical data, 
Table 2. Effect of transsphenoidal surgery on pituitary function 
Deficiency Pre-operative Post-operative p-value
GH deficiency 58/75 (77%) 76/92 (83%) ns
LH/FSH deficiency 77/103 (75%) 95/106 (90%) < 0.01
ACTH deficiency 53/101 (53%) 65/108 (60%) ns
TSH deficiency 45/106 (43%) 61/107 (57%) < 0.05
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surgery significantly increased LH/FSH (P<0.01) and TSH deficiency (P<0.05) as well as 
panhypopituitarism (P<0.001). Pre-operative prolactin levels < 2 µg/L (n=19) were not 
associated with significant higher rates of pre-operative or post-operative pituitary defi-
ciencies. Transient diabetes insipidus occurred in 28% of cases. After surgery there was 
a significant decrease in prolactin levels in both women and men (p<0.01). In women 
mean prolactin decreased from 29.1 ± 25.3 µg/L to 9.4 ± 9.1 µg/L; in men from 14.1 ± 
13.7 µg/L to 4.3 ± 3.3 µg/L. 
Long-term post surgical follow-up (Figure 1)
Ninety-seven patients could be assessed for recurrence with a mean follow-up period of 
6.0 ± 3.7 years and a median follow-up period of 5.0 years (range 1-14 years). Residual 
tumor was present in 70 patients. Six of the 97 patients had received postoperative 
radiotherapy. 
Long-term tumor control of NFMA in our series was achieved in the absence of re-
growth/recurrence in 90% of all patients. Tumor regrowth was observed in 9 patients, 
after a mean follow-up of 6.3 years (Range 3-11 years). In one patient, initially classified 
as 2B macroadenoma, recurrence occurred after 12 year follow-up. In the six patients 
treated with prophylactic radiotherapy no tumor regrowth was observed. For the total 
cohort the tumor growth free survival rates, 5 and 10 years after initial surgery, were 94% 
and 81%. In patients with residual tumor on MRI, regrowth free survival rates 5 and 10 
years after initial surgical treatment, were 92% and 74% (Figure 1). In patients without 
Figure 1. Kaplan Meier curve for growth-free survival rates in patients with and without residual tumor
Figure 3.1. Kaplan Meier curve for growth-free survival rates in patients with and without residual 
tumor 






































residual tumor, recurrence free survival rates 5 and 10 years after initial surgical treatment 
were 100% and 100%. 
Tumor regrowth was associated with an increase in visual field defects in 4 patients. 
Tumor regrowth and recurrence were treated by radiotherapy (n=9) and by repeat sur-
gery followed by radiotherapy (n=1). 
Binary logistic regression analysis was performed to determine possible independent 
predictors for tumor growth. The following parameters were evaluated: gender, prophy-
lactic radiotherapy, follow-up duration, any positive immunohistochemistry, positive im-
munohistochemistry for ACTH, parasellar/infrasellar tumor extension and residual tumor 
on MRI. Follow-up duration was the only independent predictor (P<0.05) for tumor 
growth. Although analysis pointed towards residual tumor as an independent predictor 
for regrowth, this did not reach statistical significance (P=0.1). 
Ten patients died during the follow-up period. The main causes of death were ma-
lignancy (n=3), cardiovascular disease (n=2) and cerebrovascular disease (n=2). There 
where no deaths due to cerebral malignancies. 
DISCUSSION
This study demonstrates that transsphenoidal surgery without postoperative radiotherapy 
is an effective and safe treatment strategy for NFMA, at least for the duration of follow 
up presented in this study. Long-term tumor control of NFMA in our series was achieved 
in the absence of regrowth/recurrence in 90% of all patients. Even in the case of residual 
tumor, in 87% no tumor regrowth was observed. These data, observed after six years of 
follow-up, do not justify prophylactic postoperative radiotherapy. Moreover, even in the 
case of regrowth during long-term follow-up, radiotherapy is still effective to stabilize or 
regress tumor growth (5). With this restrictive treatment strategy, the majority of patients 
will not be exposed to potential long-term sequelae of radiotherapy, whereas in patients 
with recurrences, the starting point of radiotherapy is delayed for several years. 
Six patients received post-surgical radiotherapy, because of large residual tumor (n=3) 
or residual tumor with strongly positive immunostaining for ACTH (n=3). The reason for 
radiotherapy in ACTH-positive tumors was mainly historical. Previous studies proposed 
that there was a higher regrowth rate in ACTH-positive tumors (14;19). However, in 
a recent study from Bradley et al, positive immunostaining for ACTH did not seem to 
increase recurrence rates (20). In the worst-case scenario, in case the six patients would 
have developed tumor regrowth without radiotherapy, the rate of patients without tu-
mor regrowth or recurrence in our series would still be 85%. Moreover, even if tumor 
growth occurred in 15% of all patients, this does not justify prophylactic postoperative 
radiotherapy. 
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Perioperative mortality was minimal in our series (0.9%) and comparable with those 
reported in other studies (3;4;7). Visual field defects improved in more than 80% of the 
patients, which is comparable with other studies in which improvement of visual field 
defects have been reported in 75-100% (3;4;14;21). Surgical treatment in our study did not 
reverse pituitary deficiencies. We summarized previous studies on the effect of transsphe-
noidal surgery on pituitary function in NFMA in Table 3 because the data of these studies 
are conflicting. Some studies report, to a variable degree, an improvement in pituitary 
function (21-25), whereas others could not demonstrate significant improvement in pitu-
itary function (3;9;26) or even reported a decrease in pituitary function (8;27). Therefore, 
the aim of transsphenoidal surgery should be improvement of visual field defects, rather 
than improvement of pituitary function. 
We found 11 previous studies that evaluated the effects of long-term follow up after 
transsphenoidal surgery, with and/or without postoperative radiotherapy, on tumor con-
trol of NFMA. These studies are all retrospective studies like our study. These studies 
differed with respect to the selection of patients with NFMA. In 5 studies results of long-
term follow-up in selected, non-consecutive groups of patients after surgery for NFMA are 
presented (Table 4, (14;20;28-30)). In those studies, patients were selected from postop-
erative patients with NFMA only if they had not received radiotherapy and did not have 
locally invasive tumors (28;30), only if gross removal of the tumor was achieved (29), 
or only if immunostaining was positive for ACTH (14;20). During long term follow up 
without postoperative radiotherapy, tumor growth rates in those studies ranged between 
6 and 35% (20;28-30). Postoperative radiotherapy for NFMA with positive immunostaining 
for ACTH resulted in a regrowth rates of 20% versus 35% without radiotherapy (20). 
In Table 5, we have summarized other seven studies (including our study), which 
evaluated the effects of long-term follow-up in unselected, consecutive patients after 
surgery for NFMA (3-6;9;15;29).In some of these studies (5;9) postoperative radiotherapy 
was applied in a small number of patients. The main problem in the interpretation of the 
therapeutic value of postoperative radiotherapy is that the indications for postoperative 
radiotherapy were not clearly defined in some of the studies (6;9). The study of Park et 
al. provided postoperative radiotherapy, when tumor removal was incomplete (5). Re-
growth rates in patients without postoperative radiotherapy ranged between 11 and 46%, 
whereas regrowth rates after postoperative radiotherapy ranged between 2-36% during 
long term follow up. There is a suggestion of a benefit of postoperative radiotherapy on 
long term tumor recurrence in some (5;6) but not in all studies (4). Therefore, the true 
benefit of postoperative radiotherapy is not straightforward in individual patient care. 
Finally, from Tables 4 and 5 it becomes evident that the average duration of follow-up 
in all series is limited to only 4.3-7.4 years after surgery. Prolongation of the follow-up 
duration may result in a higher rate of recurrence or regrowth than appreciated by the 
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The possible benefit of postoperative radiotherapy, i.e. a decrease in long-term re-
growth rate of NFMA, has to be balanced against potential side effects of radiotherapy. 
The contribution of postoperative radiotherapy to the development of pituitary deficien-
cies is independent of tumor regrowth (10-12). Increased mortality is reported in patients 
with hypopituitarism, compared with age-matched controls (31-34). In addition to very 
rare complications such as optic nerve atrophy and visual deterioration (12;35;36), there 
is about 2.5% cumulative risk of second brain tumors 20 year after radiotherapy (13;37). 
Finally, there are indications that radiotherapy for pituitary adenomas may adversely 
affect quality of life (38). Nonetheless, postoperative radiotherapy might be considered 
in selected patients with incomplete tumor removal, large residual tumor and panhypo-
pituitarism. 
Tumor regrowth occurred in nine patients, and tumor recurrence in only one patient. 
In only four of these patients, increase in tumor volume was accompanied by visual 
field defects. This indicates, that in a ‘wait-and-see-policy’, MRI-scanning is the principal 
method for detection of tumor regrowth/recurrence because ophthalmologic assessment 
can still be normal at the time tumor growth can already be detected by MRI. 
In conclusion, transsphenoidal surgery for NFMA is a safe and effective procedure, 
without evidence for tumor growth in 90% of all patients after six years follow-up. Based 
on the data presented in this study, we advocate a postsurgical wait-and-see procedure, 
which will prevent unnecessary exposure to potential sequelae of radiotherapy in the 
majority of patients. Additional studies are required to assess tumor control during pro-
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Objective. Improvement of visual field defects continues even yr after the initial surgical 
treatment. Because this process of continuing improvement has not been documented for 
visual acuity, we audited our data to explore the pattern of recovery of visual acuity until 
one year after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. 
Design. Retrospective follow-up study
Patients. Forty-four patients (mean age 56 ± 14 yr), treated by transsphenoidal surgery 
for nonfunctioning pituitary macroadenoma, were included in this analysis.
Results. Visual acuity improved significantly within three months after transsphenoidal 
surgery. The mean visual acuity increased from 0.65 ± 0.37 to 0.76 ± 0.36 (p<0.01) (right 
eye), and from 0.60 ± 0.32 to 0.82 ± 0.30 (p<0.01) (left eye). Visual acuity was improved 
one year after transsphenoidal surgery compared to the three months postoperative val-
ues. The mean visual acuity increased from 0.76 ± 0.36 to 0.82 ± 0.34 (p<0.05) (right eye), 
and from 0.82 ± 0.30 to 0.89 ± 0.27 (p<0.05) (left eye).
Conclusion. Visual acuity improves progressively after surgical treatment for nonfunc-
tioning pituitary macroadenomas, at least within the first year after transsphenoidal sur-
gery.
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INTRODUCTION
Nonfunctioning pituitary macro-adenomas (NFMA) are the most prevalent macro-adeno-
mas (1;2). Patients with NFMA mainly present with decreased visual acuity, visual field 
defects and hypopituitarism, caused by mass effects of the tumor (3-5). Transsphenoidal 
surgery is the treatment of choice, resulting in improvement of visual field defects in 75-
100% of all patients (3-5). Accordingly, visual acuity improves in the majority of patients 
(6-10), although visual field defects and visual acuity may worsen in a limited number of 
patients after surgery (6;7;9;10). 
The process of visual field recovery starts directly after surgery and can already be 
documented on the second postoperative day (11). This process of recovery is probably 
due to restoration of the velocity of conduction. However, improvement of visual field 
defects continues even yr after the initial surgical treatment (12;13). Although a reduced 
visual acuity is correlated with the extent of visual field defects (13;14), postoperative 
changes in visual acuity do not parallel changes in visual fields in every case (6). 
To our knowledge, the process of gradual visual improvement has only been ob-
served for visual field defects, but not for visual acuity (12). This is, however, clinically 
relevant since improvement of minor visual field defects can occur unnoticed, whereas 
improvement in visual acuity is almost invariably noticed, and can potentially overcome 
thresholds to previous impairments in daily life. We therefore audited our data to explore 
the pattern of recovery of visual acuity until one year after transsphenoidal surgery for 
nonfunctioning pituitary macroadenoma. 
PATIENTS AND METHODS
Patient selection
Forty-four patients, mean age 56 ± 14 yr, were included in this retrospective analysis. 
In order to obtain a homogenous cohort for assessment, the inclusion criteria were the 
following:
1. Transsphenoidal surgery for nonfunctioning pituitary macroadenoma (diameter > 1 
cm) for compression of the optic chiasm 
2. Assessment of visual acuity at least once before surgery and at least twice in the first 
year after surgery 
3. The availability of two postsurgical MR scans within a time frame of maximal three 
months of the ophtalmological assessments 
To overcome the potential effect of postoperative tumor-regrowth on visual outcome, pa-
tients were excluded from analysis if the one-year post-operative scans revealed growth 







For complete assessment, we reviewed the patient records of all departments involved 
in the treatment of NFMA (Endocrinology, Neurosurgery, Ophthalmology). Endocrine (pi-
tuitary function) and ophthalmologic data (visual acuity and visual fields) were assessed 
before surgery, 3, and 12 months after surgery. An MRI was performed before surgery, 
3-6 months, and 12-15 months after surgery. Transsphenoidal surgery was performed by 
one of two neurosurgeons. 
Corrected visual acuity was determined by the Snellen chart (15;16) and was scored for 
both eyes. Visual fields were assessed by Humphrey perimetry in all patients. Goldman 
perimetry was used as an additional tool to assess peripheral visual field defects. 
Definitions
The diagnosis of nonfunctioning pituitary macroadenoma was based on two criteria: 1) 
the presence of a pituitary macroadenoma (>1cm) on MRI, 2) the absence of overproduc-
tion of any of the pituitary hormones. In all cases the diagnosis was histological con-
firmed. Tumor extension was classified as suprasellar, parasellar/infrasellar or combined 
suprasellar and parasellar/infrasellar extension. 
In all patients, visual acuity was scored on a scale between 0 and 1.25. Visual field 
defects were scored semi-quantitative and classified as mild, moderate or severe. Visual 
field defects were classified as mild, if there were peripheral defects in only one quadrant. 
Defects were classified as moderate if the upper quadrants were affected, whereas in 
combined upper and lower quadrant field defects these were classified as severe. 
Growth hormone (GH) deficiency was defined as an insufficient rise in GH levels 
(absolute value < 3 µg/L) after stimulation during an insulin tolerance test (ITT). When 
secondary amenorrhoea was present for more than 1 year premenopausal women were 
defined as LH/FSH deficient. Postmenopausal women were defined as LH/FSH deficient 
when gonadotropin levels were below the normal post-menopausal range (LH < 10 U/l, 
FSH < 30 U/l). In men, LH/FSH deficiency was defined as a testosterone level below the 
reference range (8.0 nmol/L). TSH deficiency was defined as a total or free T4 level below 
the reference range. ACTH deficiency was defined as a basal cortisol level at 8.00 A.M. 
of < 0.12 µmol/l and/or an insufficient increase in cortisol levels (absolute value < 0.55 
µmol/ l) after an ITT. 
Statistical analysis:
The paired t-test was used for paired samples. SPSS software version 12.0 (SPSS Inc., 
Chicago, IL, USA) was used. A P-value of < 0.05 was considered statistically significant. 
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RESULTS
Preoperative patient characteristics (Table 1)
Forty-four patients, 52% male, were included in this study. Radiological imaging by MRI 
revealed a macro-adenoma in all patients with suprasellar extension in 100% and para-
sellar/infrasellar extension in 41% of cases. Hypopituitarism was present in 80% of all 
patients and panhypopituitarism in 25%. 
Preoperative assessment of visual function (Table 1)
Visual fields were normal in 9% (5/44) off all patients. Transsphenoidal surgery in these 
patients was performed for apoplexia (n=1) and because compression of the optic chiasm 
was evident on the MR scan (n=4). Of all patients with visual field defects 59% were clas-
sified as severe, 17% as moderate, and 12% as mild. Mean visual acuity was 0.65 ± 0.37 
for the right eye, 0.60 ± 0.32 for the left eye. 
Visual acuity was assessed twice before surgery in 34 patients (77% of total). The me-
dian time between the first and the second pre-surgical assessment was 4 weeks (range 
1-45). No significant decrease in visual acuity was observed within this time period. The 
mean visual acuity for the two pre-surgical assessments was: 0.65 ± 0.37 vs 0.66 ± 0.38 
(right eye), and 0.60 ± 0.32 vs 0.62 ± 0.33 (left eye). Moreover, no decrease in visual 
acuity was observed in patients (n=13) with a time interval of > 8 weeks between the first 
and the second pre-surgical assessment.
Table 1. Patient characteristics before transsphenoidal surgery
Male/female 23/21
Age (yr ± SD) 56 ± 14
Visual acuity 
Oculus dexter (mean ± SD) 0.67 ± 0.37






















All patients were treated by transsphenoidal surgery. Repeat surgery within 6 months af-
ter initial treatment was performed twice (large residual tumor mass (n=1) and persisting 
liquor leakage (n=1)). Repeat surgery was performed by transcranial approach.
Transsphenoidal surgery was followed by radiotherapy in 10 patients in order to pre-
vent recurrence. Patients received 40 Gy (n=5) or 46 Gy (n=5).
Three months postoperative assessment of visual function
After transsphenoidal operation in patients with preoperative visual field defects im-
provement was observed in 60% and normalisation of the visual fields in 32%. In 1 patient 
there was a slight increase in visual field defects. 
Visual acuity improved significantly three months after transsphenoidal surgery (Figure 
1). The mean visual acuity increased from 0.65 ± 0.37 to 0.76 ± 0.36 (p<0.01) (right eye), 
and from 0.60 ± 0.32 to 0.82 ± 0.30 (p<0.01) (left eye).
One-year postoperative assessment of visual function
One year after initial surgical therapy visual field defects showed continuous improve-
ment in 35% patients, compared with early postoperative results. In 80% of these patients, 
this improvement was accompanied by continuous improvement of visual acuity. 
Figure 1. The pattern of improvement of visual acuity after transsphenoidal surgery for nonfunctioning 
pituitary macroadenomas (n=44)
Figure 4.1. The pattern of improvement of visual acuity after transsphenoidal surgery for 
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In 55% of all patients (n=24), visual acuity shows continuing improvement until one 
year after surgery. In 8 of them, this improvement was not accompanied by further 
improvement of visual field defects. Visual acuity was improved one year after trans-
sphenoidal surgery compared with the three months postoperative values (Figure 1). The 
mean visual acuity increased from 0.76 ± 0.36 to 0.82 ± 0.34 (p<0.05) (right eye), and 
from 0.82 ± 0.30 to 0.89 ± 0.27 (p<0.05) (left eye).
DISCUSSION
The main aims of surgery in nonfunctioning pituitary macroadenomas are restoration of 
visual acuity and visual field defects by decompression of the optic chiasm. Nonethe-
less, our data indicate that there is no necessity for immediate decompression since 
postponement of surgery for several weeks did not result in deterioration of visual acuity. 
Moreover, in this series of 44 patients, we demonstrated a continuing improvement of 
visual acuity until one year after transsphenoidal surgery. 
There is a significant correlation between the severity of visual loss prior to surgery and 
persisting visual field defects (9;13;14). In our patients in whom visual acuity was assessed 
twice before surgery, no decrease of visual acuity was observed with a median time in-
terval between two measurements of 4 weeks. This indicates that postponing surgery for 
one month does not negatively influence visual outcome, which is in line with the slow 
growth pattern of nonfunctioning adenomas (4). Nonetheless, the delay of surgery should 
not unnecessarily be prolonged because a significant, inverse, correlation between visual 
outcome and the prolonged duration of symptoms has been reported (9).
The initial event in the pathogenesis of decreased visual function in pituitary mac-
roadenomas is compression of the optic chiasm. Nerve compression leads to decreased 
conduction and demyelination. In an experimental setting, the process of demyelination 
after nerve compression has been observed even after two days (17;18). In case of con-
tinuous nerve compression remyelination can be observed after several weeks, although 
remyelinated fibres do not seem to reach normal thickness and organisation structure, 
and complete demyelinated fibres co-exist (17;18). Re-myelinated fibers restore conduc-
tion, at least partially, even if the causative nerve lesion is still existing (19;20). The im-
provement of visual dysfunction after surgical treatment is supposed to consist of two, or 
probably even three, phases (12). There is an early phase, comprising the first hours and 
days after surgery. In this early fast phase, the improvement is caused by decompression 
of the visual pathways, leading to a restoration of signal conduction. Visual recovery has 
been demonstrated in the first days after surgical treatment (11;12). The second phase, 
i.e. delayed recovery, is pathophysiologically caused by restoration of axonal transport 







delayed recovery may last for several yr (12;13). A precise boundary between the end 
of the fast phase of recovery and the start of the delayed recovery seems to be artificial, 
because these two phases reflect different pathophysiological mechanisms, which may 
co-exist for a certain time-period. The contribution of the first phase of recovery might be 
larger, given the fact that more than 50% of eventual recovery takes place within the first 
three months after surgery (13).
It is already known that visual acuity improves in the first months after surgical treat-
ment (6-10) and that the improvement of visual field defects is a continuing process for 
at least one year (12;13). Kerrison et al. (12) showed progressive improvement of visual 
fields even more than two yr after surgical decompression of the optic chiasm. However, 
they did not demonstrate this same pattern of recovery for visual acuity. This might be 
due to the relative small number of patients during prolonged follow-up. In the present 
study we demonstrate that also improvement of visual acuity continued one year after 
surgical treatment. 
The clinical consequences of the delayed phase of recovery for both visual field defects 
and visual acuity are obvious. Follow-up of patients after surgical treatment for pituitary 
macroadenomas should include ophthalmologic assessment within several weeks after 
surgery, as well as subsequent assessments after one and two years, in order to estimate 
the final effect of surgery on visual function. Moreover, patients should be told that visual 
function can continue to improve at least until one year after surgery. The relevance 
of these findings is obvious and is of importance to all patients, given the impact of a 
decreased visual acuity as an independent predictor for a decreased quality of life (21;22). 
Moreover, these data are essential in order to evaluate potential effects of recurrent pitu-
itary adenomas on visual function.
Ten patients in our series received postoperative radiotherapy. However, it is unlikely 
that this treatment affected the results of our study. In a series reported by Gnanalingham 
et al. (13), in which 34% of all patients received postoperative radiotherapy, persistent 
improvement of visual field defects was documented even yr after surgical therapy. In 
another series of 21 patients, 2 yr after pituitary irradiation, there were no cases of radia-
tion-induced visual field or visual acuity deterioration (23). 
In conclusion, this study demonstrates that the improvement of visual acuity after trans-
sphenoidal treatment for nonfunctioning pituitary macroadenomas consists of both an 
early and a delayed phase of recovery. After initial post-surgical recovery, a progressive 
delayed improvement of visual acuity at least until one year after transsphenoidal surgery 
is likely to occur.
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Objective. Several studies have reported increased mortality in patients with pituitary 
tumors after surgical treatment. However, it is presently unknown to what extent this 
excess mortality is caused by pituitary tumors and their treatment in general, and to what 
extent by previous exposure to hormonal overproduction. The aim of the present study 
was to compare relative mortality risks between patients previously treated for Cushing’s 
syndrome and for nonfunctioning pituitary macroadenomas. 
Patients and Methods. We included 248 consecutive patients with pituitary adenomas 
treated by transsphenoidal surgery in our hospital for nonfunctioning pituitary macroad-
enomas (NFMA) (n=174) and ACTH producing adenomas (n=74). The standardized mor-
tality ratio (SMR) was calculated for the whole cohort, as well as for the two diseases 
separately. Cox regression analysis was used to estimate the relative risk for mortality of 
patients with Cushing’s disease compared with NFMA patients. 
Results. The mean duration of follow up after surgery was 10.1 ± 7.2 years for the whole 
cohort. Patients with Cushing’s disease (39.1 ± 16.1 yr) were significantly younger at time 
of operation than patients with NFMA (55.3 ± 13.4 yr).The SMR for the whole cohort was 
1.41 (95% CI 1.05-1.86). The SMR in NFMA patients was 1.24 (95% CI 0.85-1.74) versus 
2.39 (95% CI 1.22-3.9) in patients with Cushing’s disease. In patients with Cushing’s 
disease, compared with NFMA, the relative age-adjusted mortality risk was significantly 
increased: 2.35 (95% CI 1.13-4.09, P=0.008). 
Conclusion. The relative risk for mortality in patients previously treated for Cushing’s 
disease was increased, compared with NFMA. This implies that previous, transient over-
exposure to cortisol is associated with increased mortality.
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INTRODUCTION
Pituitary adenomas are benign neoplasms associated with considerable morbidity due 
to mass effects, hormonal overproduction and pituitary insufficiency. In nonfunction-
ing pituitary macroadenomas (NFMA) morbidity is caused by mass effects of the tumor 
leading to visual field defects, decreased visual acuity and pituitary insufficiency in the 
majority of patients (1). In functioning pituitary adenomas morbidity is caused by hor-
monal overproduction, in addition to tumor mass effects in cases of macroadenomas. In 
Cushing’s disease, cortisol excess causes central obesity, insulin resistance, hypertension, 
hyperlipidemia and osteoporosis (2;3). Moreover, cortisol overproduction is associated 
with increased cardiovascular risk, continuing even after remission of the disease (4;5). 
In addition to increased morbidity, a number of studies have reported increased mor-
tality in patients with pituitary tumors (6-10) and associated conditions such as hypopi-
tuitarism (11-13). In the majority of these studies the general population was used as a 
control group to assess mortality risk in patients with pituitary adenomas. However, this 
approach is not able to make a distinction between the effects of hormone overproduc-
tion per se versus the general aspects of the pituitary tumor and their treatment, on mor-
tality. Therefore, we performed a single center study to assess mortality ratios during long 
term follow up after transsphenoidal surgery in patients with nonfunctioning pituitary 
macroadenomas and Cushing’s disease. To answer the question to which extent previous 
exposure to hormonal overproduction per se is associated with increased mortality, we 
compared mortality in patients operated for Cushing’s disease to mortality in patients 
operated for NFMA. 
PATIENTS AND METHODS
Patients
All 248 consecutive patients treated at the Leiden University Medical Center (LUMC) 
between 1977 and 2005 by primary transsphenoidal surgery for NFMA (n=174) and 
Cushing’s disease (n=83) were eligible for inclusion in the study. The majority of these 
patients were described in previous studies (1;14). For mortality analysis, information 
on emigration, death or survival was available for all patients. Nine of the patients with 
Cushing’s disease were excluded from the analysis, because the initial treatment, prior 
to transsphenoidal surgery, consisted of unilateral adrenalectomy followed by pituitary 
irradiation. Therefore, we included 74 patients with Cushing’s disease in the analysis.
Clinical, endocrinological, visual and radiological preoperative assessment was avail-







within the first 2 months after surgery, and, subsequently, every 6-12 months during 
prolonged follow-up. 
Diagnostic criteria and criteria for cure/recurrence
NFMA was diagnosed, if there was a pituitary macroadenoma without clinical or bio-
chemical evidence of hormonal overproduction. The diagnosis of Cushing’s disease was 
made on clinical grounds together with biochemical confirmation, based on the following 
tests: increased 24 h urinary excretion of free cortisol (24 h UFC, criterion > 220 nmol/24 
h), failure of serum cortisol to suppress following low-dose dexamethason (1 mg), sup-
pression of serum cortisol during a 7h intravenous dexamethason suppression test (15), 
and an normal or exaggerated response of serum ACTH and cortisol to intravenous CRH 
stimulation (16). In patients with Cushing’s disease, in whom a pituitary adenoma was not 
visualized by MRI, selective inferior petrosal sinus sampling was performed. A central to 
peripheral ACTH gradient of > 2 (basal) or 3.5 (after CRH) was considered confirmative 
for an ACTH-producing adenoma. 
Tumor recurrence in patients with NFMA was defined as an increase in tumor volume 
on sequential radiological imaging. Biochemical cure in Cushing’s disease was defined as 
a normal suppression of serum cortisol levels to 1 mg oral dexamethason (cortisol < 100 
nmol/L the following morning) and normal 24 urine free cortisol excretion in 2 consecu-
tive samples. Persistent Cushing’s disease was defined as a failure to fulfil biochemical 
criteria for remission 3-6 months after the first operation (14). Relapse of Cushing’s dis-
ease was defined as recurrence of hypercortisolism, using the abovementioned criteria 
for Cushing’s disease. 
Assays
Until 1986 cortisol was measured by in house RIA with an interassay coefficient of varia-
tion of 10%. Between 1986 and 1994 a fluorescence energy-transfer immunoassay Syva 
Advance (Syva Company, Palo Alto, CA) was used, with an interassay variation coefficient 
of 3.6 to 6.1%. From 1994 cortisol was measured by fluorescence polarisation assay on 
a TDx (Abbott, Abbott Park, Ill). The interassay variation coefficient is 5-6% above 0.5 
µmol/l and amounts to 12% below 0.20 µmol/l. 
Hormonal evaluation and treatment
Growth hormone (GH) deficiency was defined by an IGF-1 level below the reference 
range for age and sex (17), and/or an insufficient rise in GH levels (absolute value < 3 
µg/L) after stimulation during an insulin tolerance test (ITT). ACTH deficiency was de-
fined by a basal cortisol level at 8.00 A.M. of < 0.12 µmol/l and/or an insufficient increase 
in cortisol levels (absolute value < 0.55 µmol/ l) after an insulin tolerance test (ITT: nadir 
glucose < 2.2 nmol/L). When secondary amenorrhoea was present for more than 1 year 
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premenopausal women were defined as LH/FSH deficient. Postmenopausal women were 
defined as LH/FSH deficient, when gonadotrophin levels were below the normal post-
menopausal range (LH < 10 U/l, FSH < 30 U/l). In men, LH/FSH deficiency was defined 
by a testosterone level below the reference range (8.0 nmol/L). TSH deficiency was 
defined as a total or free T4 level below the reference range. In case of ACTH deficiency 
patients were treated with hydrocortisone (standard treatment regimen: 20mg daily) and 
TSH deficiency was treated with levothyroxine. In case of LH/FSH deficiency men were 
substituted with testosterone and women < 50 years with estrogen replacement. From 
1994 onwards, patients with documented GH-deficiency were treated with rhGH. 
Tumor size classification and radiological follow-up
Radiological imaging was performed by CT (until 1985) and subsequently by MRI. Tumor 
size was classified according to Hardy (18). For the present study, the classification was 
simplified to microadenoma (Hardy I 0), noninvasive macroadenoma (Hardy II 0, A, B, C) and 
invasive macroadenomas (with suprasellar or parasellar invasive growth; i.e. Hardy II D,E, 
Hardy III 0-E and Hardy IV0-E). In patients with NFMA imaging was performed within one 
year after the initial surgical treatment and subsequently MRI scanning was performed 
every second year. In patients with Cushing’s disease repeat radiological imaging was 
performed in case of persistent or recurrent disease, or, according to the judgement of 
the treating physician.
Treatment (Table 1)
All 248 patients were operated by transsphenoidal approach. Postoperative, conventional 
radiotherapy was applied in 50 cases in order to prevent recurrence in NFMA, or to treat 
persistent active Cushing’s disease. Recurrent disease in NFMA was treated by radio-
therapy, by repeat surgery, or both. Persistent or recurrent disease in Cushing’s disease 
was treated by bilateral adrenalectomy, radiotherapy, repeat surgery or a combination of 
these treatment modalities. 
Statistics and mortality analysis
We used two different methods to assess mortality in patients with pituitary adenomas. 
First, we calculated the SMR for the whole cohort, as well as for the two different pituitary 
diseases included in the study, i.e. NFMA and Cushing’s disease. Normal mortality rates 
for the Dutch population were obtained from the Dutch Central Bureau of Statistics (The 
Netherlands) using mortality rates per sex, age groups of 5 yr, and calendar periods of 
5 yr (1975, 1980, 1985, 1990, 1995 and 2000). Expected mortality rates were determined 
based on the person-years follow-up for each sex and age group and each calendar 
period and compared with the observed mortality rate. Second, we used cox-regression 







justed for sex and age at the time of operation. We did not correct for tumor volume and 
hypopituitarism, because, although these factors might be associated with mortality, they 
are closely associated with the underlying diagnosis. Data are expressed as mean ± SD, 
unless otherwise mentioned. The chi-squared test was used for categorical data. 
RESULTS 
Patients and treatment (Table 2)
We included 248 consecutive patients in this study, who were transsphenoidally operated 
for NFMA (n=174) and Cushing’s disease (n=74). The mean duration of follow-up for the 
total cohort was 10.1 ± 7.2 years, comprising a total of 2497 person-years. The mean age 
at time of operation was significant younger in patients with Cushing’s disease (39.1 ± 
16.1 yr), compared with patients with NFMA (55.3 ± 13.4 yr, P<0.001). Female gender 
was more prevalent in Cushing’s disease (77%) than in NFMA (44%, P<0.001). All NFMA 
patients had a macroadenoma, because clinically nonfunctioning microadenomas are in 
general not operated. Patients with Cushing’s disease had a high prevalence of micro-
adenomas (85%). Preoperative pituitary insufficiency was significantly more prevalent in 
NFMA patients (85%), compared with patients with Cushing’s disease (5%) (P<0.001).
Treatment and treatment outcome (Table 1)
Long-term tumor control, i.e. the absence of radiological evidence of tumor recurrence, 
was achieved in 84% of all NFMA patients. Tumor recurrence in NFMA was treated by 
radiotherapy (n=14), surgery (n=4) or combined surgery and radiotherapy (n=5). In 3 
Table 1. Treatment characteristics 
NFMA (n=174)
Transsphenoidal surgery 174












For persistent disease 7
For recurrent disease 6
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other patients a wait and see approach was undertaken after recurrence of the adenoma, 
because of high age and serious comorbidity. 
Eighty % of the patients operated for Cushing’s disease achieved initial remission. Eight 
patients relapsed after initial remission. Persistent disease (n=15) or recurrent (n=8) dis-
ease was treated by repeat surgery (n=4), radiotherapy (n=8), or a combination of these 
treatment modalities with or without adrenalectomy (n=9). In 2 patients a wait-and-see 
approach was undertaken, because of high age (n=1) and because the patient refused ad-
ditional treatment (n=1). These two patients were alive at the time of the final evaluation. 
Long-term remission of Cushing’s disease was achieved in 93% of all patients. 
Mortality 
During a mean follow-up period of 10 years, 47 patients with a mean age 71.1 ± 12.0 
years died (NFMA n=35, Cushing’s disease n=12). The all cause mortality was 20% in 
NFMA patients and 16% in Cushing’s disease. However, the mean age at death was 
younger in patients with Cushing’s disease (62.4 ± 11.5 yr) compared with patients with 
NFMA (74.1 ± 10.7 yr, p<0.05). Causes of death were cardiovascular disease in 23.4%, 
cerebrovascular disease in 12.8%, malignancy in 19.1% and infectious diseases in 17% of 
all patients. The cause specific mortality for NFMA and Cushing’s disease is provided in 
Table 3. One patient with Cushing’s disease died because of persistent severe Cushing’s 
disease, despite multimodality treatment. 
Standardized mortality ratios (Table 3)
A total of 2497 person-years was available for comparison with normative data of the 
Dutch population. The SMR for the whole cohort, derived from the observed: expected 
ratio (47:33.2), was 1.41 (95% CI 1.05-1.86). 
The SMR in NFMA patients was 1.24 (95% CI 0.85-1.74), whereas in patients with 
Cushing’s disease the SMR was 2.39 (95% CI 1.22-3.9). 
Table 2: Patient characteristics
Nonfunctioning macroadenoma Cushing’s disease
Number of patients 174 74
Age at operation (yr) 55.3 ± 13.4 39.1 ± 16.1
M/F 98/76 18/56
Mean follow-up (yr) 9.1 ± 6.6 12.8 ± 7.3
Radiological characteristics
Microadenoma 85%
Non-invasive macroadenoma 70% 11%
Invasive macroadenoma 30% 4%
Pituitary function
Preoperative pituitary insufficiency 85% 5%
Postoperative pituitary insufficiency 91% 23%







Mortality in Cushing’s disease compared with nonfunctioning adenomas (Figure 1)
We performed cox-regression analysis to assess the effect of two different diseases, NFMA 
and Cushing’s disease, on mortality. In the regression analysis we adjusted for age at 
initial operation, and sex, because age and sex distribution were significantly different 
between the two study groups. We used the NFMA patients as reference group, and 
estimated the relative mortality risk of patients with Cushing’s disease. 







Number of deaths 47 35 12 








Cardiovascular 11 7 4
Malignancies 9 8 1
Infectious 8 7 1
Cerebrovascular 6 5 1
Persistent disease despite multimodality treatment 1 1
Unknown 5 3 2
Other 7 5 2
Figure 1 Mortality in patients treated for nonfunctioning macroadenoma, acromegaly and Cushing’s disease 
(cox-model, corrected for age and gender)
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In patients with Cushing’s disease, compared with NFMA, the relative mortality risk 
was significantly increased: 2.35 (95% CI 1.13-4.09, P=0.008). By regression analysis, in 
a model adjusted for age and gender, radiotherapy and hypopituitarism were not associ-
ated with increased mortality risk. The relative mortality risk of patients with Cushing’s 
disease in whom the disease persisted after initial surgical treatment was increased (RR 
6.21, 95% CI 1.46-26.4) compared with patients who were cured by initial surgery. 
DISCUSSION
In the present single center study we assessed mortality rates during long-term follow up 
of patients with NFMA and Cushing’s disease after treatment by transsphenoidal surgery. 
The mortality of these patients was increased by 41%, compared with the expected rate 
of the general population, despite adequate treatment. The relative risk for mortality in 
Cushing’s disease was increased, compared with that in NFMA. Moreover, the mortality 
risk was increased in patients with persistent Cushing’s disease after operation compared 
with cured patients. This implies that transient overexposure to cortisol is associated with 
increased mortality, and that mortality risk seems to be correlated with the duration of 
overexposure to cortisol. 
Mortality in pituitary adenomas is associated with general aspects of pituitary tumors 
and their treatment, but also with disease specific morbidity. We compared patients with 
Cushing’s disease to patients treated for NFMA in order to assess the possible role of 
hormonal excess in increased mortality, because patients treated for NFMA lack cortisol 
excess specific for Cushing’s disease. The patients presented in this single-center study 
are comparable in several aspects. First, the time of inclusion was comparable between 
NFMA and Cushing’s disease. Second, all patients underwent transsphenoidal surgery as 
primary treatment. Third, patients were operated by the same team of neurosurgeons. 
This is important because treatment outcomes after transsphenoidal surgery have shown 
to be different among different centers and are dependent on the experience of the 
surgeon (19). Fourth, all patients underwent the same follow-up and treatment regi-
men, especially with respect to hormonal substitution. Despite these similarities, patients 
treated for NFMA still differ from Cushing’s disease for relevant factors, in addition to the 
lack of overproduction to cortisol: size of the adenomas, pituitary insufficiency, age and 
sexratio. In patients with NFMA, by definition, macroadenomas are more prevalent than 
in patients with Cushing’s disease. Therefore, in most patients the mass effects of the 
adenomas are greater in NFMA patients, resulting in higher rates of pituitary insufficiency 
in NFMA than in Cushing’s disease. However, this would adversely affect prognosis in 
NFMA rather than that in Cushing’s disease. Therefore, even if adenoma size and pituitary 







rather than increased, the difference between both patient groups. Finally, Cushing’s 
disease is associated with a much younger age of the patients compared with NFMA 
and a higher preponderance of female patients. These discrepancies are inherent to the 
clinical phenotypes of both pituitary diseases. We addressed the confounding affects of 
differences in age and sex ratios between both patient groups on mortality risk by com-
paring the mortality rates of both groups separately to the mortality rates per sex and age 
groups of 5 yr of the Dutch population. By this way, we could compare the mortality risk 
between NFMA and Cushing’s disease despite differences in age and sex ratio. 
Contributors to the increased mortality risk in pituitary tumors in general are, factors 
related to treatment and to hypopituitarism. Transsphenoidal surgery is associated with a 
peri-operative mortality of only ~ 0.9% (19;20). The peroperative mortality in our study 
was 0.8% (n=2). Results of the effects of radiotherapy on long-term mortality are conflict-
ing (7;12;21;22). In our study, the application of radiotherapy was not associated with 
excess mortality. However, this issue requires further investigation, because the compari-
son between irradiated and non-irradiated patients is not straightforward. Potential bias is 
introduced because the indication for radiotherapy has changed over time, and a longer 
period after radiotherapy is required before remission established. Hypopituitarism, pres-
ent in the majority of patients treated for pituitary macroadenomas, is associated with 
increased mortality (11;12). Although the exact mechanisms by which hypopituitarism 
might cause an increase in mortality is unclear, it is suggested that hypopituitarism is 
associated with premature vascular disease (13;23-25). Several authors point towards the 
role of untreated GH-deficiency in this respect (13;26). 
In our study we found an 1.2 fold increased mortality in NFMA patients compared with 
the general population, although this difference was not significant. However, mortality 
was 1.7 fold increased in a larger series with more than 500 NFMA patients (12). In that 
study, a substantial part of the patients was operated by transcranial approach, which 
might, at least in part, account for the difference in estimated standardized mortality 
ratios.
Cushing’s syndrome is a fatal condition in the absence of adequate treatment (27). 
Recent studies have reported SMR in treated patients with Cushing’s disease ranging from 
1.0 to 3.8 (9;10;28;29). However, confidence intervals in these studies were broad. In the 
present study mortality in patients treated for Cushing’s disease was 2.4 fold increased 
compared with the general population. Moreover, mortality risk after transsphenoidal sur-
gery for Cushing’s disease was also increased compared with NFMA patients, who were 
treated identically. This points towards effects of previous exposure to cortisol excess on 
mortality risk in patients with Cushing’s disease. The importance of cortisol in mortal-
ity excess is further underscored by the fact that mortality is increased in patients with 
persistent Cushing’s disease after treatment, compared with cured patients (28;30). This 
indicates that the duration of exposure to overproduction of cortisol is a major contribu-
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tor to the increased mortality risk observed in Cushing’s disease. Cortisol excess induces 
central obesity, diabetes mellitus, hyperlipidemia and hypertension (2). There is evidence 
that the increased cardiovascular risk in Cushing’s disease continues even after remission 
of the disease (3;4). Therefore, the effects of transient cortisol overproduction may not be 
reversible with respect to certain biological properties that influence mortality. 
In order to further evaluate our conclusion that cortisol excess is responsible for the 
increased mortality in Cushing’s disease, we also compared mortality in Cushing’s dis-
ease to mortality in patients with acromegaly. These mortality data from our center in 
patients with acromegaly after transsphenoidal surgery have been published previously 
(22). Compared with acromegaly the mortality risk, adjusted for sex and age, in patients 
with Cushing’s disease was 2.4 fold increased (95% CI 1.13-4.91) (See Figure 1). This 
indicates that the increased mortality in patients with Cushing’s disease is not due to 
hormonal overproduction in general, but due to intrinsic properties of the exposure to 
cortisol excess. 
In conclusion, this study demonstrates that mortality in patients after transsphenoidal 
surgery for pituitary tumors is increased. Moreover, the relative mortality risk is increased 
in patients with Cushing’s disease compared with both NFMA and acromegaly. This im-
plicates that transient exposure to cortisol excess is a major contributor of the increased 
mortality, even after cure of Cushing’s disease. This observation may also be of relevance 
for patients treated with exogenous glucocorticoids for non-endocrine diseases.
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Objective. Although a reduced quality of life (QoL) has been reported after long-term cure 
of functioning pituitary adenomas, the effect of successful treatment of nonfunctioning 
pituitary macroadenoma (NFMA) on QoL has not been fully addressed. Therefore, we 
evaluated a broad spectrum of QoL parameters in patients successfully treated for NFMA 
in our center.
Design. Case-control study.
Patients and Methods. We assessed QoL in 99 adult patients (mean age 61.9, range 
24-86 yr), in remission during long-term follow up after surgical (n=99) and additional 
radiotherapeutic (n=37) treatment for NFMA by four validated health-related question-
naires (HADS, MFI-20, NHP, SF-36). Patient outcomes were compared with 125 controls 
and with age-adjusted reference values derived from literature.
Results. NFMA patients reported significantly impaired QoL in all questionnaires, 
compared with the 125 controls and the age-adjusted reference values. All subscales of 
fatigue, assessed using the multi-dimensional Fatigue Index (general fatigue, physical 
fatigue, reduction in activity, reduction in motivation, mental fatigue) were impaired. The 
scores in the Nottingham Health Profile pointed towards reduced energy and affected 
emotional reaction. In several subscales of the Short Form-36 (social functioning, role 
limitations due to physical problems, role limitations due to emotional problems and 
general health perception) NFMA patients reported a reduced QoL.
Conclusion Quality of Life is considerably reduced in patients after successful treatment 
of NFMA.
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INTRODUCTION 
Nonfunctioning pituitary macroadenomas (NFMA) are the most prevalent pituitary mac-
roadenomas (1;2). The main symptoms are visual field defects and hypopituitarism, 
which are caused by mass effects of the tumor. Transsphenoidal surgery is considered 
the treatment of choice, because medical therapy in general is ineffective to reduce tumor 
size. Visual field defects improve in more than 80% of all patients after surgery (3-6). 
In contrast, hypopituitarism does not improve in most patients after surgery for NFMA 
(5;7-9). To prevent tumor recurrence, selected patients may be treated by postoperative 
radiotherapy (10). 
In general, pituitary diseases are associated with impaired quality of life (QoL) (11). 
This can be explained by several factors. Macroadenomas are associated with differ-
ent degrees of hypopituitarism, which require hormonal substitution. However, despite 
optimal endocrine replacement strategies, hypopituitarism is associated with impaired 
QoL parameters (12;13). Moreover, Growth hormone (GH) and ACTH producing adeno-
mas may induce irreversible effects, which persist despite long-term cure of the disease 
(12;13). Finally, an association between applied radiotherapy and decreased QoL has 
been reported (12;14).
Most studies on QoL in pituitary diseases were not focussed on NFMA, but included 
heterogeneous groups, consisting of both functioning and nonfunctioning pituitary tu-
mors (11;15-17). To our knowledge, no studies on QoL in patients treated for NFMA, 
compared with healthy controls, have been published. Therefore, in the present study the 
aim was to assess QoL in adult NFMA patients treated by transsphenoidal surgery. Patient 
outcomes of QoL parameters were compared with those of control subjects as well as 
to age-adjusted reference values derived from literature. We evaluated physical, psycho-
logical, and social aspects of QoL in patients after long-term cure, using four validated, 
health-related QoL-questionnaires covering a broad spectrum of physical, psychological 
and social health: HADS, MFI-20, SF-36 and NHP. 
PATIENT AND METHODS. 
Protocol
A total of 128 consecutive patients with NFMA, treated by transsphenoidal surgery in 
our center between 1985 and 2004, were identified. QoL questionnaires were sent to 
their homes in prepaid envelopes. After three months non-responders were contacted by 
telephone to encourage completion and return of the questionnaires. Each patient was 
also asked to provide a control person of comparable age and sex to serve as a control 







area. In addition to this control group, we used reference data from healthy subjects of 
the Dutch and west European population, obtained from studies reporting normal age-
adjusted values (18-22). 
All patients were seen at least twice yearly by an endocrinologist, with adequate evalu-
ation and treatment of possible deficiencies of pituitary hormones. Evaluation of ACTH 
deficiency and GH deficiency was performed by insulin-tolerance test. Previous studies 
have demonstrated that patients with multiple pituitary hormone deficiencies, including 
two or more pituitary hormone deficiencies other than GH deficiency, had a likelihood of 
approximately 95% of harbouring GH deficiency (23-25). Based on these data, we classi-
fied patients in whom GH-stimulation test data were lacking, but who were deficient in 
3 other pituitary axes, as GH deficient. In addition, the biannual evaluation consisted of 
measurement of free T
4
 and testosterone (male patients). If results were below the lower 
limit of the respective reference ranges, substitution with thyroxine or testosterone was 
started. In the case of amenorrhea and low estradiol levels in premenopausal women, 
estrogen replacement was provided. 
The medical ethics committee of the Leiden University Medical Centre approved the 
study protocol. 
Patients and controls (Table 1)
One-hundred-and-sixteen of 128 (91%) patients returned the questionnaires, 17 of whom 
preferred not to participate. Twelve patients did not respond. Thus, 99 completed ques-
tionnaires were received (77%). The study-population had a mean age of 61.9 yr, (range 
24-86 yr). No significant differences in age, gender and tumor characteristics were found 
between the study-population, and the patients who preferred not to participate or who 
did not return the questionnaires.
Sixty-six controls were provided by the 99 patients who returned the questionnaires 
(67%). The control group was extended by controls derived from other studies in our 
center, who had been similarly approached (12;13). The total control group consisted of 
125 controls (66 males, 59 females), with a mean age of 61.5 yr, range 26-86 yr. Age and 
gender from the control group were not significantly different from the studied NFMA 
patients.
Study parameters
Primary study-parameters were the results of the four health-related QoL questionnaires. 
The results were linked to characteristics (age and gender) of the patients, treatment 
characteristics (surgery, radiotherapy, and multiple surgical procedures), the presence of 
pituitary deficiencies and visual field defects. 
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Questionnaires
HADS (Hospital Anxiety and Depression Scale) The HADS consists of 14 items per-
taining to anxiety and depression. Each item is measured on a four-point scale. Scores for 
the anxiety and depression subscale range from 0-21 and for the total score from 0-42. A 
high score points to more severe anxiety and depression (26). A total score of 13 or more 
was considered increased. Age-related Dutch reference values of the general population 
were derived from the study of Spinhoven et al. (20).
MFI-20 (Multidimensional Fatigue Index) The MFI-20 contains 20 statements to 
assess fatigue (27). Five different dimensions of fatigue (four items each) are calculated 
from these statements: 1) general fatigue, 2) physical fatigue, 3) reduced activity, 4) re-
duced motivation, and 5) mental fatigue. Every statement is measured on a 5-point scale; 
scores vary from 0 to 20. Higher scores indicate higher experienced fatigue. Age-related 
Dutch reference values were derived from Smets et al. (19).
NHP (Nottingham Health Profile) The NHP is frequently used in patients with 
pituitary disease to assess general well-being and QoL. The survey consists of 38 yes/no 
questions, which are subdivided in 6 scales assessing impairments, i.e. pain (8 items), 
energy level (3 items), sleep (5 items), emotional reactions (9 items), social isolation (5 
items) and disability/functioning, i.e. physical mobility (8 items) (28;29). Subscale scores 
are calculated as a weighted mean of the associated items and are expressed as a value 
between 0 and 100. The total score is the mean of the 6 subscales. A high score is related 
to a worse QoL. Age-related West-European reference values were derived from the study 
from Hinz et al. (18). 
SF-36 (Short Form-36) The SF-36 questionnaire comprises 36 items and records 
general well being during the previous 30 days (30;31). The items are formulated as 
statements or questions to assess eight health concepts: 1) physical functioning, 2) social 
functioning, 3) limitations in usual role activities because of physical health problems, 4) 
pain, 5) general mental health (psychological distress and well-being), 6) limitations in 
usual role activities because of emotional problems, 7) vitality (energy and fatigue), and 
8) general health perceptions and change in health. Because the HADS and the MFI-20 
are more specific questionnaires for mental health and fatigue, the vitality and general 
mental health items were left out in this evaluation. Because the scores for the 8 items 
are calculated separately from exclusive item-specific questions (21), the results of the 
SF-36 items presented in this study are not influenced by the 2 items we left out in this 
evaluation. Scores are expressed on a 0-100 scale. Higher scores are associated with 









SPSS for windows version 12.0 (SPSS Inc., Chicago, IL) was used for data analysis. Data 
are expressed as mean ± SD, unless otherwise mentioned. We used unpaired T-tests 
to compare patient and control data. Using stepwise linear regression analysis we as-
sessed independent variables that affect QoL. Results of the linear regression analysis 
are expressed as the absolute standardized β of independent predictive factors. One-way 
ANOVA analysis was performed to compare QoL scores of three different groups: Patients 
without GH deficiency, patients with GH deficiency, substituted with recombinant human 
(rh)GH and patients with GH deficiency without rhGh substitution). Differences were 
considered statistically significant at P <0.05.
RESULTS
Patient and treatment characteristics (Table 1)
Patient characteristics are detailed in Table 1. All 99 patients had been treated by trans-
sphenoidal surgery. Twenty-two patients had received prophylactic postoperative ra-
diotherapy. Repeat surgery within 6 months after initial treatment was performed in 8 
patients for a large residual tumor mass (n=4), persisting liquor leakage (n=3) or profuse 
bleeding (n=1). The mean follow-up period after initial surgical treatment was 9.9 ± 6.6 
yr. In 17 patients tumor recurrence was observed by MRI scanning, after a mean follow-
up duration of 7.1 ± 4.0 yr. Tumor recurrence was treated by radiotherapy (n=11), or a 
combination of surgery and radiotherapy (n=4). In the remaining 2 patients an expectant 
approach was undertaken. 
At the time of evaluation, 83% of the patients were GH deficient, 82% were LH/FSH de-
ficient, 63% were ACTH deficient and 62% were TSH deficient. Hypopituitarism, defined 
as pituitary deficiency in at least one axis, was present in 93 of 99 patients, panhypopi-
tuitarism of the anterior pituitary gland in 48%. Diabetes insipidus was present in 9% of 
the patients. All patients with ACTH and TSH deficiency received hormonal substitution 
therapy. Of all GH deficient patients, 42 (51%) received rhGh substitution at the time of 
evaluation. Of all GH deficient patients without substitution at time of evaluation, rhGH 
was stopped in 8 cases. 
Finally, visual field defects were present in 41% of cases. 
Quality of Life in NFMA-patients compared with controls and age-adjusted reference-values (Table2):
NFMA patients reported an impaired QoL compared with the 119 controls and the age-
adjusted reference values. The QoL scores were significantly reduced in 19 out of 21 
subscales as compared with own controls, and in 10 out of 21 subscales as compared 
with age adjusted reference values. 
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Compared with own controls, in patients with NFMA, all subscales of the MFI-20, as-
sessing different aspects of energy/fatigue, were affected. The majority of items assessed 
by the SF-36 and the NHP, two questionnaires covering multiple aspects of general health 
and well-being, were affected (with the exception of pain (NHP and SF-36) and health 
change (SF-36)). On the 3 subscales of the HADS, NFMA patients performed worse 
compared with own controls. 
Compared with age-adjusted reference values, the majority of subscales of the MFI-20 
were affected, with the exception of general fatigue. According to the SF-36 scores of 4 
out of 7 subscales were reduced (social functioning, role limitations due physical, emo-
tional problems and general health perception). Only two subscales of the NHP (energy 
and emotional reaction) pointed toward a reduced QoL in NFMA patients. There was no 
significantly affected QoL parameter according to the HADS questionnaire, compared 
with age adjusted reference values. 
The effect of GH deficiency and GH replacement on QoL
A substantial proportion (49%) of the NFMA patients with GH deficiency were not sub-
stituted with rhGH. To assess the effect of GH deficiency and rhGH replacement on QoL, 
we performed ANOVA analysis comparing three groups: patients without GH deficiency 
(n=16), patients with GH deficiency, substituted with rhGH (n=42) and patients with GH 
deficiency, but without rhGh substitution (n=41). The only significant difference between 










Mean IGF-I SD score in rhGH substituted patients 
Mean IFG-I SD score in GH deficient, non-substituted patients
LH/FSH deficiency
ACTH deficiency
Mean daily dose of hydrocortisone (mg) in substituted patients
TSH deficiency
Mean free T4 levels (pmol/L) in substituted patients (normal 10.0-24.0)
Any degree of hypopituitarism
Two or more pituitary deficiencies
Panhypopituitarism of the anterior pituitary gland
Diabetes insipidus
































these three groups was in sleep performance (NHP, P < 0.05). Sleep was most affected in 
patients with a GH deficiency, substituted with rhGH. 
Linear regression 
Stepwise uni-variate linear regression analysis was performed in a model including: gen-
der, age, radiotherapy, multiple operations, ACTH-deficiency, TSH deficiency, LH/FSH 
deficiency, GH deficiency, multiple pituitary deficiencies and visual defects as indepen-
dent variables, and the questionnaire items as dependent variables. 
Age was an independent predictor for reduced physical ability (NHP, standardized β = 
0.48, P<0.01) and reduced physical function (SF-36, standardized β = 0.48, P < 0.01). The 
presence of multiple hormonal deficiencies was an independent predictor for role limita-
tions due to physical problems (SF-36, standardized β = 0.28, P < 0.05), impaired social 
functioning (SF-36, standardized β = 0.29, P < 0.05) and sleep (NHP, standardized β = 
0.25, P < 0.05) and increased general fatigue (MFI-20, standardized β = 0.24, P< 0.05). LH/
Table 2. Quality of Life parameters (HADS, MFI-20, NHP, SF-36) in treated NFA patients compared with 
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1 patients compared with own controls. 
2 derived from references 18-22. 
3 patients compared with literature reference data
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FSH deficiency was an independent predictor for reduced activity (MFI-20, standardized β 
= 0.28, P < 0.05) and increased physical fatigue (MFI-20, standardized β = 0.25, P < 0.05). 
Female gender was an independent predictor for increased anxiety (HADS, standardized 
β = 0.35, p < 0.05). Radiotherapy, visual field defects and GH deficiency were not found 
to be independent predictors for reduced QoL in any of the questionnaires.
DISCUSSION
The data in this study indicate that quality of life is reduced in patients successfully 
treated for NFMA. According to the parameters tested by the HADS, MFI-20, NHP and SF-
36 questionnaires, patients reported a decreased QoL in 10 out of 21 subscales, compared 
with both age-adjusted reference values and controls. Almost all subscales of the MFI-20, 
assessing energy/fatigue, showed a significant decreased QoL. Linear regression analysis 
revealed the presence of multiple pituitary deficiencies, and, to a lesser extent age, as the 
predominant predictors of a decreased QoL. 
In the present study, NFMA patients were compared with own controls and age-adjust-
ed reference values derived from literature. The advantage of using own controls is that 
they are from the same geographic area and socio-economic class as the patients (32). 
However, these controls might be subject to a selection bias, because patients might have 
chosen controls with a supposed good health status (33). To overcome this potential bias, 
we also compared the NFMA patients to age-adjusted reference values from the literature. 
Moreover, the use of two different control groups might lead to more credible results if 
the results are consistent (32). The scores of the NFMA patients showed an impaired QoL 
in more subscales of the four questionnaires, compared with own controls than compared 
with the age-adjusted reference-values, confirming the possible difference in health status 
between the two groups. Nonetheless, even compared with the reference data obtained 
from the literature, our NFMA patients scored worse, supporting our conclusions with 
respect to the negative effect of NFMA on QoL. Although the response rate in our series 
of patients with NFMA was 91%, and completed questionnaires were received of 77% of 
the patients, it seems unlikely, that the non-responders have influenced the outcome of 
our study, because there were no differences in patient characteristics between respond-
ers and non-responders/decliners.
Literature on QoL in patients with NFMA is scarce. To our knowledge only two studies 
evaluated QoL in NFMA patients (11;14). Johnson et al. reported a reduced QoL in NFMA 
patients, before treatment, using the SF-36 questionnaire, compared with scores from the 
normal population (11). Other reports on QoL in NFMA, consisting of heterogeneous 
groups of patients with both functioning and nonfunctioning tumors, showed a reduced 







to perform subgroup analysis in order to estimate QoL specifically in NFMA, because of 
the small number of patients (15;34). Moreover, the effects of pituitary diseases on QoL 
cannot simply be generalized for all pituitary diseases. NFMA patients differ from patients 
with functioning pituitary adenomas in several aspects. NFMA is more prevalent in older 
and male patients compared with functioning pituitary adenomas (36). Nonfunction-
ing adenomas are treated only when tumor size indicates a macroadenoma, whereas 
treatment indication in functioning adenomas is focused at hormone overproduction in 
addition to tumor size. Therefore, pituitary tumors in treated NFMA tend to be larger than 
tumors in patients treated for functioning pituitary adenomas. In accordance, in NFMA 
patients there is a higher degree of pituitary deficiencies, whereas patients cured from 
functioning pituitary tumors also suffer from irreversible effects of previous hormone 
overproduction, as is the case in functioning adenomas such as Cushing’s disease or 
acromegaly (12;13). Compared with NFMA, QoL in acromegaly patients is clearly de-
creased (17). QoL-assessment in heterogeneous groups, consisting of both functioning 
and nonfunctioning adenomas, may therefore not be an appropriate strategy to assess 
QoL in patients treated for NFMA.
The study from Page et al. did not reveal a reduced QoL in surgically treated NFMA 
patients, compared with patients after mastoid surgery (14). The results of the SF-36 
questionnaire from these patients after mastoid surgery are summarized in Table 3. These 
results do not show concordant differences compared with our NFMA patients, pointing 
toward a general role for medical illness in impaired QoL. However, this also underscores 
the notion that the SF-36 questionnaire is not disease-specific, i.e. is not specific for the 
assessment of QoL in patients with pituitary diseases. 
Our results point toward a reduced QoL in physical and psychological as well social 
items. Treated NFMA patients report increased fatigue, both mental and physical, reduced 
energy and role limitations due to physical problems as well as reduced activity and re-
duced motivation. Interestingly, physical functioning seemed not to be affected compared 
with age adjusted reference values. NFMA patients also report affected emotional reac-
tions, role limitations due to emotional problems as well as affected social functioning. 
Table 3. Summary of SF-36 results in patients treated for nonfunctioning pituitary macroadenomas and in 




Mean age (yr) 62 61
Physical functioning 79 ± 23 71 ± 31 
Physical role 65 ± 40 74 ± 40
Emotional role 69 ± 40 83 ± 35
Social functioning 79 ± 23 83 ± 26 
Bodily pain 81 ± 21 76 ± 25
Health perception 57 ± 24 68 ± 21
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Nonetheless, the HADS questionnaire did not reveal any significant difference between 
NFMA patients and age-adjusted reference values. This finding is in accordance with the 
report of Korali et al. in which no elevated rates of mental disorders could be found after 
treatment for NFMA, even in the case of multiple pituitary deficiencies (37). 
We could not properly assess the effect of hypopituitarism per se on QoL, because 
hypopituitarism was present in 93% of all NFMA patients. Although the number of pa-
tients with hypopituitarism seems rather high, it is comparable to the percentage (94%) 
of patients with hypopituitarism presented in a series of consecutive patients treated for 
NFMA in our hospital (38). The patient population in the present series seems therefore 
not skewed towards those patients with more severe disease. Hypopituitarism was found 
to be an independent predictor of reduced QoL in patients treated for Cushing’s disease, 
affecting both physical and psychosocial items (13). In the present study, the presence 
of multiple pituitary deficiencies was the most predominant predictor for decreased QoL, 
pointing toward an important role of pituitary function for optimal QoL. Hormonal sub-
stitution therapy does not reproduce the normal plasma hormone profiles of healthy 
individuals. Moreover, the effects of hormones in general are difficult to quantify at the 
tissue level. Consequently, titration of endocrine replacement therapy is possible only 
within certain physiological limits. These intrinsic imperfections in endocrine replace-
ment therapy may result in subtle physiological derangements. Most importantly, this im-
perfection in endocrine substitution may result in a decreased QoL. In this study LH/FSH 
deficiency was an independent predictor for reduced activity and increased physical fa-
tigue. This may reflect the lack of sensitive signs and symptoms for monitoring adequacy 
of testosterone and estrogen substitution (39). We did not measure routinely levels of 
dehydroepiandrostenedione (DHEA). However, we recently documented in a random-
ized placebo-controlled trial, that DHEA substitution superimposed on GH-substitution 
did not substantially improve QoL in patients with secondary adrenal failure (40). In this 
study, female gender was an independent predictor for anxiety. The predisposition for 
female gender as an independent risk factor for a decreased QoL is unclear, and has been 
previously described in patients with primary brain tumors (41). However, it does not 
seem to be a disease specific phenomenon given the fact that QoL studies in nonpituitary 
diseases (malignancies, coronary heart disease, inflammatory bowel disease) also report 
decreased QoL in female patients as compared with male patients (41-45). 
GH deficiency was not found to be an independent predictor for any of subscales 
of the four questionnaires. In our study only 51% of all GH deficient patients received 
rhGH substitution. We could not detect a beneficial effect of rhGH substitution on QoL 
scores. However, this study was, in strict sense, not designed to assess the effect of rhGH 
substitution on QoL. A recent meta-analysis on the effect of rhGh substitution on various 
QoL subscales, suggested that rhGH substitution does not improve QoL compared with 







suggesting that in selected patients rhGH substitution may have a beneficial effect on 
QoL (51). 
The four health-related questionnaires used in this study, were not disease-specific, i.e. 
they were not developed to assess QoL in NFMA, although the NHP is frequently used in 
patients with pituitary disease. However, we found a reduced QoL in the majority of sub-
scales of the MFI-20, the SF-36 and the NHP. This seems to point toward a strong overall 
effect of the pituitary diseases on general health and well being of both the physical and 
the psychosocial aspects. 
In conclusion, Quality of Life is reduced in patients after successful treatment of NFMA. 
According to the MFI-20, NHP and SF-36, patients reported a decreased QoL in almost 
all subscales compared with age-adjusted reference values and controls. The presence of 
multiple pituitary deficiencies was the predominant predictor for a reduced QoL.
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Objective. Quality of Life (QoL) has become increasingly important in the evaluation of 
treatment of pituitary and hormonal diseases. A reduced QoL has been reported in child-
hood onset craniopharyngioma; however, reports of QoL in adult craniopharyngioma 
patients are scarce. In the present study, we assessed QoL in adult patients successfully 
treated for craniopharyngioma in our centre.
Design. Case-control study.
Methods. In this study we assessed QoL in 29 adult patients in remission during long-
term follow-up after treatment for craniopharyngioma. Four validated health-related 
questionnaires (HADS, MFI-20, NHP, SF-36) were used, covering multiple aspects of 
physical, psychological and social functioning. Patient outcomes were compared to con-
trols (n=142) and to age adjusted reference values derived from literature.
Results. General fatigue, physical fatigue, energy, physical condition and physical mo-
bility were significantly impaired, compared to controls. The main independent predic-
tors for a decreased QoL were visual field defects (depression, total HADS score, activity, 
motivation and energy), female gender (depression, motivation and pain), and, to a lesser 
extent, repeat surgery (role limitations due to emotional problems), and radiotherapy 
(mental fatigue). 
Conclusion. Adult patients treated for craniopharyngioma show persistent impairment 
in Quality of Life, especially in the physical subscales. 
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INTRODUCTION 
Craniopharyngiomas are histologically benign brain tumours arising from the remnants of 
Rathke’s pouch. Despite their benign appearance, their clinical behaviour is aggressive, 
causing serious morbidity by damaging the optic chiasm, the pituitary, and hypothalamic 
area. Currently, craniopharyngioma is treated primarily by transsphenoidal or transcranial 
surgery, whereas post-surgical radiotherapy is not routinely applied in all patients (1;2). 
Recurrent disease is treated by repeat surgery and/or radiotherapy. 
In adults, treatment of craniopharyngioma is associated with excessive multi-system 
morbidity and increased mortality during long-term follow-up despite a high cure rate 
(3-6). There is a high incidence of pituitary insufficiencies, and visual field defects may 
persist in some patients (1-4). Finally, there is a high incidence of cardiovascular risk 
factors in these patients (1;3;4).
Pituitary diseases in general are associated with decreased quality of life (QoL) and 
cognitive dysfunction, despite optimal replacement strategies for pituitary insufficiency, 
and long-term cure of hormone excess syndromes such as Cushing’s disease and acro-
megaly (7-10). Hypopituitarism and radiotherapy are important factors for impaired QoL. 
Reduced QoL has been reported in childhood onset craniopharyngioma (3;11-13). To 
our knowledge, QoL in adult craniopharyngioma patients has been reported in only one 
study (3). In this study, QoL was markedly reduced, as assessed by two questionnaires 
(NHP and QoL-AGHDA), the latter being a disease specific questionnaire, designed to 
assess physical and psychological discomfort in adult growth hormone deficiency. Given 
the high prevalence of associated morbidity found in our adult craniopharyngioma pa-
tients (4), we wanted to extend these observations by assessment of QoL in more detail. 
In the present study we assessed QoL in adult patients successfully treated for cranio-
pharyngioma in our centre. We evaluated physical, psychological, and social aspects of 
QoL in patients after long-term cure, using four validated, health-related QoL-question-
naires. Patient outcomes were compared with own control values as well as to age-ad-
justed reference values derived from literature.
PATIENTS AND METHODS
Protocol
Forty-three patients treated and cured for craniopharyngioma, followed in our centre 
from 1965 to 2002, were identified. Four QoL-questionnaires were sent to their homes. 
They were asked to participate and to complete, and return the questionnaires in a 
prepaid envelope. Non-responders received a reminder letter. Thereafter, they were con-







Patients were also asked to provide a control person with comparable age and sex (for 
example a relative – not the partner –, friend or neighbour) in order to compose a control 
population with similar socio-economic status derived from the same geographical area. 
In addition to this control group, we used literature reference data from healthy samples 
of the Dutch and west European population from studies reporting normal age-adjusted 
values (14-18). These data are based on larger study populations than our own controls 
and are therefore not affected by a potential positive selection by the patients. 
The medical ethics committee of the Leiden University Medical Centre approved the 
study protocol.
Patients and controls (Table 1)
Thirty-three of 43 (77%) patients returned the questionnaires, four of whom preferred not 
to participate. Thus, 29 completed questionnaires were received. The study population of 
29 patients (15 males) had a mean age was 47.9 ± 17.6 years (range 11-80 yr). All patients 
were primarily treated by surgery. Nine patients received radiotherapy, four of whom for 
recurrence. Seven patients had repeat surgery. Mean follow-up after primary surgery was 
19.9 ± 13.1 years and all patients were cured of disease. Hypopituitarism was present in 
93% of cases. No significant differences in age, gender and tumour characteristics were 
found between the study population and the patients who did not return the question-
naires.
Twenty-five controls returned completed questionnaires. The control group was ex-
tended by controls derived from other studies performed at our centre, who had been 
similarly approached (7;9). Therefore, the total control group consisted of 142 controls 
(88 females, 54 males), with a mean age of 53.8 ± 14.5 yr. No significant differences in 
QoL measures were present between the three control groups, justifying their combined 
use. Age and gender were not significantly different from the studied craniopharyngioma 
patients. 
Study parameters
Primary study-parameters were the results of four health-related QoL questionnaires. The 
results were linked to patient characteristics (age and sex), applied treatments (surgery, 
radiotherapy and multiple surgical procedures), presence of hypopituitarism and visual 
impairments. Hypopituitarism was defined as one or more pituitary hormone deficien-
cies.
Questionnaires
HADS (Hospital Anxiety and Depression Scale) The HADS consists of 14 items per-
taining to anxiety and depression. Each item is measured on a 4-point scale. The range 
of scores for the anxiety and depression subscale is 0-21 for the total score 0-42. A high 
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score points to more severe anxiety and depression (19). Age-related Dutch reference 
values of the general population were derived from the study of Spinhoven et al. (16).
MFI-20 (Multidimensional Fatigue Index) The MFI-20 contains 20 statements to 
assess fatigue (20). Five different dimensions of fatigue (four items each) are calculated 
from these statements: 1) general fatigue, 2) physical fatigue, 3) reduced activity, 4) re-
duced motivation and 5) mental fatigue. Every statement is measured on a 5-point scale; 
scores range from 0 to 20. Higher scores indicate higher experienced fatigue. Age-related 
Dutch reference values were derived from Smets et al. (15).
NHP (Nottingham Health Profile) The NHP is frequently used in patients with 
pituitary disease to assess general well-being and QoL. The survey consists of 38 yes/no 
questions, subdivided into the following 6 scales assessing impairments: 1) pain (8 items), 
2) energy level (3 items), 3) sleep (5 items), 4) emotional reactions (9 items), 5) social 
isolation, (5 items), and 6) disability/functioning, i.e. physical ability (8 items) (21;22). 
Subscale scores are calculated as a weighted mean of the associated items and are ex-
pressed as a value between 0 and 100. The total score is the mean of the 6 subscales. 
Higher scores are related to worse QoL. Age-related west-European reference values 
were derived from the study from Hinz et al. (14). 
SF-36 (Short Form-36) The SF-36 questionnaire comprises 36 items and records 
general well being during the previous 30 days (23;24). The items are formulated as 
statements or questions to assess eight health concepts: 1) physical functioning, 2) social 
functioning, 3) limitations in usual role activities because of physical health problems, 4) 
pain, 5) general mental health (psychological distress and well-being), 6) limitations in 
usual role activities because of emotional problems, 7) vitality (energy and fatigue), and 
8) general health perceptions and change in health. Because the HADS and the MFI-20 
are more specific questionnaires for mental health and fatigue, the vitality and general 
mental health items were left out in this evaluation. Scores are expressed on a 0-100 
scale. Higher scores are associated with better QoL. Age-related west-European reference 
values were derived from the Dutch publications of Van Zee et al. (17;18).
Statistics
SPSS for Windows version 12.0 (SPSS Inc., Chicago, IL) was used to perform data analy-
sis. Data are expressed as mean ± SD unless otherwise mentioned. We used unpaired 
T-tests to compare patient and control data. Using linear regression analysis, we assessed 
independent variables that affect quality of life. Differences were considered statistically 








Patient characteristics (Table 1 and Figure 1)
Clinical characteristics are detailed in Table 1. Primary surgery was performed in all 29 
patients. Nine (31%) patients received radiotherapy after primary surgery, and seven 
patients (24%) needed more than one operation. The different treatment modalities are 
summarized in Figure 1. At the time of evaluation in two patients pituitary function was 
intact. These two patients were both reoperated because of tumor regrowth and suffered 
both from visual field defects. Five (17%) patients had pituitary deficiency in 3 of 4 axes. 
In the majority of patients (76%), panhypopituitarism was present. Twelve (41%) patients 
had persistent visual impairments. 
Table 1. Characteristics of the craniopharyngioma patients and controls.
Craniopharyngioma patients (n=29) Controls (n=142)
Age (years)
Male/Female




















53.8 ± 14.5 (P = NS)
88/54 (P = NS)
NS denotes not significant.
* Defined as pituitary deficiency in more than 1 axis
** Defined as pituitary deficiency in all four axes
Figure 1. Patient groups, stratified according to different treatment modalities.
Figure 7.1. Patient groups, stratified according to different treatment modalities.  
RT denotes radiotherapy. 
Initial surgical treatment 
Transcranially N = 20 
Transsphenoidally N = 9 
One surgical 
procedure, no RT 
           N = 14 
RT.
Prophylactic
 N = 5 
For recurrence 
N = 3 
Repeat surgery 
N = 4 
   For recurrence
N = 2 
Repeat surgery 
followed by RT 
N = 1 
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Quality of Life in craniopharyngioma patients and controls (Table 2)
Compared to the 142 controls and the age-adjusted reference values, the craniopharyn-
gioma patients had reduced QoL in every questionnaire, except for the HADS. According 
to the HADS there was no significant difference between patients and controls in items 
concerning anxiety and depression. All subscales of fatigue assessed by the MFI-20 were 
affected, especially general and physical fatigue. Reduction in activity and motivation did 
not reach statistical significance when compared with the age-adjusted reference values. 
The scores of the patients on the NHP pointed to reduced energy and physical mobility. 
Sleep, emotional reaction and social isolation scores were not significantly different from 
the controls. Health perception, as assessed by the SF-36, was significantly affected in 
craniopharyngioma patients. Moreover, physical and social functioning was reduced, as 
compared with own controls. 
Factors affecting Quality of Life in craniopharyngioma patients
Childhood- versus adult-onset craniopharyngioma. Adult-onset craniopharyngioma pa-
tients performed worse on the depression score (HADS, P < 0.05) than childhood-onset 
patients.
Gender. Compared with males, females reported a decreased QoL for several energy-
related items, such as general fatigue (MFI-20, P < 0.01), reduced motivation (MFI-20, P 
< 0.05) and energy (NHP, P < 0.01), and also for pain (NHP, P < 0.05), social functioning 
(SF-36, P < 0.05) and role limitations due to physical problems (SF-36, P < 0.05). 
Age. Younger patients were more affected on the following subscales: social isolation 
(NHP, P < 0.05) and social functioning (SF-36, P < 0.05). No age-related differences were 
found on items concerning energy and physical functioning. 
Radiotherapy. Only mental fatigue was significantly affected in patients treated by 
radiotherapy (MFI-20, P < 0.01). 
Repeat surgery. Patients who underwent multiple operations performed worse on gen-
eral fatigue (MFI-20, P < 0.05), sleep (NHP, P < 0.05) and health change (SF-36, P < 
0.01).
Visual field defects. The presence of persistent visual field defects significantly affected 
the following items: total HADS score (P < 0.05), general fatigue (MFI-20, P < 0.05), re-
duced activity (MFI-20, P < 0.01), reduced motivation (MFI-20, P < 0.01), energy (NHP, P 
< 0.01), social functioning (SF-36, P < 0.05) and role limitations due to physical problems 
(SF-36, P < 0.05).
Multiple pituitary deficiencies/panhypopituitarism. Scores from patients with intact pi-
tuitary function (n=2) indicated more reduced QoL in all subscales of the HADS and the 
MFI-20, as compared with patients with multiple pituitary deficiencies/panhypopituita-







hypopituitarism were lower, indicating a more reduced QoL; according to the NHP, no 
obvious difference in scores was observed. 
Linear regression 
Stepwise, uni-variate, linear regression analysis was performed in a model including 
gender, age, radiotherapy, multiple pituitary deficiencies/panhypopituitarism, multiple 
operations and visual defects as independent variables, and the questionnaire items as 
dependent variables. Visual field defect was an independent predictor for depression 
(HADS, P = 0.05), total HADS score (P < 0.05), reduced activity (MFI-20, P = 0.05), re-
duced motivation (MFI-20, P < 0.01) and reduced energy (NHP, P < 0.05). Female gender 
was an independent predictor for depression (HADS, P < 0.05), reduced motivation 
Table 2. Quality of Life (HADS, MFI-20, NHP, SF-36) in treated craniopharyngioma patients compared to 





























Role limitations due to physical problems

















































































































Data shown are the mean ± SD
a Patients compared with own controls by the unpaired two-tailed t-test
b Derived from references 14-18
c Patients compared with literature reference data by the unpaired two-tailed t-test
d No data available
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(MFI-20, P < 0.05) and pain (NHP, P =0.05). Radiotherapy was an independent predictor 
for mental fatigue (MFI-20, P < 0.05). Repeat surgery correlated to role limitations due to 
emotional problems (SF-36, P < 0.05). Multiple pituitary deficiencies/panhypopituitarism 
was not an independent predictor for any of the questionnaire items.
DISCUSSION 
Despite long-term cure, adult craniopharyngioma patients experience a considerable de-
crease in QoL. The decrease in QoL was mainly manifested in the physical items and, to 
a lesser extent, in psychosocial items. QoL in adult craniopharyngioma patients is mostly 
affected by visual impairments and to a lesser extent by female gender, repeat surgery 
and radiotherapy. 
The survival prognosis of patients treated for craniopharyngioma is favourable, with 
reported 10-year survival rates of approximately 90% in both adults and children (1;11;25-
27), although a lower survival rate has been reported (6). Clinical symptoms may arise 
from both tumour mass effects and effects of treatment. In addition to the well-rec-
ognized signs and symptoms secondary to hormonal deficiencies and visual deficits, 
patients experience physical and neuropsychological deficits, such as obesity and deficits 
of higher cortical function, memory, and behaviour (1;11;13). Decreased QoL in children 
treated for craniopharyngioma has been reported, affecting both physical and psycho-
social health (2;3;11-13). To date, structured QoL research in adult patients treated for 
craniopharyngioma has been studied in only one report (3). In this study, using the NHP 
and the QoL-AGHDA questionnaires, QoL was markedly reduced. Our series reports a 
broader assessment of QoL, which also focuses on fatigue and energy (MFI-20), as well 
as anxiety and depression (HADS). We applied four different questionnaires, covering 
multiple aspects of physical, psychological, as well as social functioning. 
In the present study, QoL in patients treated for craniopharyngioma proved to be 
more affected in items concerning physical performance than in psychosocial perfor-
mance. General fatigue, physical fatigue, energy, physical condition and mobility were 
significantly affected, as compared with controls. This is in agreement with the high 
prevalence of metabolic and visual morbidity found in adult craniopharyngioma, which 
is attributed to irreversible hypothalamic, and optic damage (3;4). Accordingly, the main 
independent predictors to affect QoL were found to be visual field defects, and to a lesser 
extent multiple operations, female gender and radiotherapy. However, because of the 
relative small number of patients, the results of the linear regression analysis have to be 
interpreted with caution. Multiple pituitary deficiencies or panhypopituitarism was found 
in all except two craniopharyngioma patients. Because of the small number of patients 







QoL could not statistically be assessed. Hypopituitarism was found to be an independent 
predictor of reduced QoL in patients treated for Cushing’s disease and acromegaly, affect-
ing both physical and psychosocial items (7;9). Despite optimal substitution, it is likely 
that hypopituitarism in our patient group also contributes to a reduced QoL. SF-36 scores 
from our craniopharyngioma patients, 93% of whom had pituitary deficiencies in at least 
three axes, were comparable to scores in patients with two or three pituitary deficiencies 
after treatment for nonfunctioning pituitary adenomas (8). However, compared to scores 
from treated Cushing patients with hypopituitarism (9), our craniopharyngioma patients 
report better QoL scores in all four questionnaires, pointing to a significant contribution 
of hypercortisolism on reduced QoL. 
The predisposition for female gender as an independent risk factor for a decreased 
QoL in craniopharyngioma is unclear, although it does not seem to be a disease specific 
phenomenon. In the general population female gender is also associated with higher 
scores on the NHP, indicating a lower QoL (14). QoL studies in non-pituitary diseases 
(malignancies, coronary heart disease, inflammatory bowel disease) also report decreased 
QoL in female patients as compared with male patients (28-32). 
Thirty-three of 43 (77%) patients returned the questionnaires, four of whom preferred 
not to participate because of physical invalidation. Participation of these 4 patients, how-
ever, would even have worsened QoL scores, because they suffered of serious morbidity. 
The use of controls chosen by the patients may have introduced a bias, since controls 
with a supposedly good QoL are more likely to be asked. In order to overcome this pos-
sible bias we also used validated reference data from literature (14-18). Compared with 
those age-adjusted reference values, QoL parameters were affected significantly in fewer 
subscales, than was revealed by the comparison with our own controls. This suggests 
that patients have chosen controls with a supposed good health status. Nonetheless, 
the comparison with both sources of control data revealed the same pattern, i.e. adult 
craniopharyngioma patients had seriously impaired QoL.
In conclusion, QoL in adult craniopharyngioma patients is significantly reduced com-
pared to a healthy population, especially in the physical items. The main independent 
predictor of a worse QoL is visual field defects. Despite long-term cure, treatment of 
craniopharyngioma, with the aim to prevent recurrence, does not normalize Quality of 
Life.
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In this thesis we have evaluated the effects of treatment and long-term follow-up in 
patients treated for nonfunctioning pituitary macroadenoma (NFMA) at the Leiden Uni-
versity Medical Center. In the general discussion we will address the following issues:
• Natural course and growth of nonfunctioning pituitary macroadenomas
• Treatment of nonfunctioning pituitary macroadenomas
• Follow-up strategy after surgical treatment
• Long-term effects of treatment for nonfunctioning pituitary macroadenomas
I. NATURAL COURSE AND GROWTH OF NONFUNCTIONING PITUITARY 
MACROADENOMAS
The natural course of pituitary adenomas
The natural course of NFMA is largely unknown, because the majority of patients with 
NFMA are operated. Therefore, the primary goal of the study described in chapter 2 
was to asses the natural course of NFMA. In that study, consisting of 28 consecutive 
non-operated patients with NFMA, with a mean follow-up period of more than 7 years, 
tumor growth was observed in 50% of the patients. Our results show a higher number of 
patients with tumor growth compared with the increase in tumor size in approximately 
25% of all patients presented in four other studies (1-4). The longer duration of follow-up, 
and the method of tumor measurements, might account for the higher number of patients 
with tumor growth in our series compared with previous studies. 
In pituitary microadenomas in general, tumor growth is observed in only a minority 
of the patients. Moreover, in microadenomas, the chance of tumor growth seems to 
be almost outweighed by the chance of a decrease in tumor size (2;4). Accordingly, 
the low prevalence of macroadenomas in autopsy series also suggest that growth from 
microadenoma to macroadenoma is a rare event (5). In patients with macroadenomas 
the tumor already has demonstrated a propensity for growth. Remarkably, a spontaneous 
decrease in tumor volume was observed in 29% of the patients during long-term follow-
up, whereas in 21% of all patients, tumor volume remained stable (chapter 2).
Clinical implications. Nonfunctioning pituitary macroadenomas will not invariable 
increase in tumor volume during follow-up. Even in the case of tumor growth, there is 
considerable individual variability. Moreover, tumor volume may even decrease during 
long-term follow-up. Therefore, the mere presence of NFMA, in the absence of visual 







Predictors of tumor growth
It would be a major advantage to predict tumor growth in individual patients present-
ing with NFMA, because this would allow individualized strategies for treatment and 
follow-up. Therefore, we evaluated determinants and predictors of tumor growth in our 
patients. In case of a conservative treatment strategy, only clinical characteristics can 
be used, whereas in patients after surgical treatment both clinical and histopathological 
characteristics could be used for predicting tumor growth. 
In our series of patients with non-operated NFMA, there were no independent predictors 
for increase or decrease in tumor volume as assessed by binary logistic regression (chap-
ter 2). Regression analysis was performed in a model including increase and decrease in 
tumor volume as dependent variables and age, gender, tumor volume, tumor extension, 
hypopituitarism, prolactin levels and follow-up duration as independent variables. 
Clinical implications. In non-operated patients with NFMA, no determinants are avail-
able that can predict an increase or decrease in tumor volume in individual patients.
Pituitary apoplexy
Pituitary apoplexy is an infrequent, but potential life-threatening (6), complication of 
pituitary tumors. It is caused by sudden haemorrhage or infarction of the tumor (7). The 
estimated prevalence of apoplexy in patients with pituitary tumors is less than 1% (4). In 
unselected patients with NFMA, apoplexy is the presenting sign in ~20% of all patients 
(8) (chapter 3). 
The optimal treatment for NFMA patients presenting with pituitary apoplexy is still a 
matter of debate (9-11). Because adrenal failure can be present (10;11), there should be 
no delay in steroid-replacement therapy. In patients presenting with total or near-total 
visual loss, surgical intervention is indicated. After transsphenoidal surgery visual impair-
ment and ocular paresis resolve in the majority of cases (9-11). However, conservative 
management with careful follow-up is appropriate in selected patients without, or with 
only mild, neuro-ophtalmic signs, without adversely affecting patient outcomes (9;12). 
We described four patients with NFMA, who presented with pituitary apoplexy. In 3 
of them, apoplexy was accompanied by visual field defects (Chapter 2). In all these 
3 patients visual fields normalized spontaneously within three months. In 1 of the 4 
patients with pituitary apoplexy, initial pituitary deficiencies were present in 3 of 4 axes, 
including ACTH deficiency. In this patient, pituitary deficiencies resolved spontaneously 
within three months. 
Clinical implications. Conservative management with close and careful follow-up is 
a safe initial approach in selected NFMA patients with pituitary apoplexy. 
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II. TREATMENT FOR NONFUNCTIONING PITUITARY MACROADENOMAS
Indications for surgical treatment
In general, nonfunctioning pituitary microadenoma, do not cause complaints. Because 
microadenomas do not exceed the anatomical boundaries of the sella, they do not cause 
visual field defects. The chance of tumor growth in microadenomas is almost outweighed 
by the change of a decrease in tumor size (2;4). This underscores the widely accepted 
point of view that in nonfunctioning microadenomas a wait-and-see approach is ap-
propriate.
Pituitary macroadenomas frequently induce visual field defects and pituitary insufficien-
cies (13-15). Transsphenoidal surgery is the cornerstone in the treatment of nonfunction-
ing macroadenomas. The main targets in the treatment strategy for patients with NFMA 
are the restoration of visual function and adequate long-term tumor control. Because 
pituitary macroadenomas will not invariable lead to tumor growth, visual dysfunction 
caused by the macroadenoma is the main indication for surgical treatment.
The optimal treatment strategy in patients with a nonfunctioning macroadenoma and 
normal visual fields is unclear (3;16;17). However, a more detailed analysis of the natu-
ral course of nonfunctioning pituitary macroadenomas may select patients in whom a 
conservative approach is appropriate. In our series of 28 patients in whom an expectant 
approach was undertaken, in 6 of the 14 patients with tumor enlargement, tumor growth 
was accompanied by visual field defects. Because the presence of visual field defects is 
an indication for transsphenoidal surgery, these patients were operated. This means that, 
of the total of 28 patients, after 7 years of follow-up, in only 21% surgical intervention 
was indicated (chapter 2). Moreover, in all patients operated for tumor growth and visual 
field defects, these defects improved or normalized. These data suggest that in case of 
the development of visual field defects during conservative follow-up of NFMA, surgical 
outcome still is favourable with respect to visual field defects. 
Clinical implications. The major indication for surgical treatment in patients with 
NFMA is the presence of visual field defects. In the absence of visual impairments, 
observation alone is a safe alternative for surgery in selected patients with NFMA, since 
surgery can be withheld in more than 75% of cases, without adversely affecting patient 
outcome. 
Effect of transsphenoidal surgery on recurrence during long-term follow-up
The natural course of NFMA after transsphenoidal surgery has not been fully elucidated. 
Therefore, we have evaluated the effect of transsphenoidal surgery on long-term tumor 
control in patients with nonfunctioning macroadenomas (chapter 3). The patients series 
consisted of 97 consecutive patients treated for nonfunctioning macroadenoma, of whom 







cal treatment was 6.0 years. In only 10% of all patients tumor growth was observed, after 
a mean follow-up of 6.3 years (range 3-11 years). In patients with residual tumor on MRI, 
recurrence free survival rates 5 and 10 years after initial surgical treatment were 92% and 
74% respectively (Figure 1). In patients without residual tumor, recurrence free survival 
rates 5 and 10 years after initial surgical treatment, were 100% and 100% respectively. 
Our series indicate that, after 10 years of follow-up, only 20% of the patients operated 
for nonfunctioning macroadenomas will develop tumor recurrence. However, even in the 
case of tumor recurrence after transsphenoidal surgery, there is considerable individual 
variability (chapter 3). This variability is in accordance with the variability in tumor 
growth in non-operated patients (chapter 2). Because the follow-up duration in patient-
series after transsphenoidal surgery, including our study, is limitated to only 6 years, 
prolongation of this follow-up duration may result in a higher rate of recurrence or tumor 
regrowth than appreciated by the currently available data. In this respect, a study from 
Breen et al. is of specific interest (6). In a series of operated and irradiated patients with 
NFMA, they demonstrated tumor control in 88%, 78% and 65% respectively after 10, 20 
and 30 years of follow-up. This implicates that there might be no decrease in the chance 
of tumor recurrence, even 30 years after initial treatment. 
Clinical implications. Good tumor control is achieved by transsphenoidal surgery 
without postoperative radiotherapy for nonfunctioning macroadenomas, even during 
long-term follow-up. In the considerations with respect to postoperative treatment, it 
should be noted that only a small percentage of patients will develop tumor recurrence 
during long-term follow-up.
Figure 1. Kaplan Meier curve for growth-free survival rates in patients with and without residual tumor
Figure 8.1. Kaplan Meier curve for growth-free survival rates in patients with and without residual 
tumor 
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Determinants and predictors of tumor recurrence after surgical treatment
The determinants of tumor recurrence after surgical treatment for NFMA are largely un-
known. We therefore evaluated the predictors and determinants of tumor recurrence after 
surgery. In our series of patients treated by transsphenoidal surgery, the only determinant 
of tumor recurrence was duration of follow-up (chapter 3). Gender, prophylactic ra-
diotherapy, positive immunohistochemistry for pituitary hormones, positive immunohis-
tochemistry for ACTH, and parasellar/infrasellar tumor extension were no independent 
predictors for tumor growth.
It is reasonable to assume that an increase in tumor recurrence is to be expected in 
patients in whom pituitary adenoma is not completely resected. This is the case in all 
patients with parasellar or infrasellar tumor expansion (18). In several other studies the 
presence of postoperative residual tumor on MR imaging was an independent predictor 
of tumor recurrence (19;20). In our study, the statistical analysis also pointed towards 
residual tumor as predictor for tumor recurrence, although this did not reach statistical 
significance (p=0.1). It should be realized that the methods to estimate the presence of 
residual tumor are imperfect in those patients. The opinion of the surgeon regarding the 
completeness of tumor removal, underestimates residual tumor (19). Moreover, micro-
scopic dural invasion was found in 94% of all macroadenomas with suprasellar extension 
(21). This underscores the notion that even postoperative MR imaging may underestimate 
residual tumor. 
The clinical relevance of ACTH-positive immunohistochemistry for patients with NFMA 
is still under debate. Some studies suggested a more aggressive behaviour of ACTH-posi-
tive adenomas and advised postoperative radiotherapy in these patients (22-24). How-
ever, increased recurrence rates in patients with ACTH-positive immunostaining could 
not be shown in the majority of the reports (19;22;25), like in our study (chapter 3). 
Although DNA ploidy is frequently used to distinguish benign from malignant neo-
plasms, this is not a predictor for tumor growth in NFMA (26). Moreover, no correlation 
was found between histological proliferation and apoptosis markers and tumor recur-
rence (27), nor between nuclear atypia and tumor behaviour (26). A correlation has 
been described between Ki-67, a marker for cell proliferation, and tumor invasiveness, 
although this is not established in all reports (24). Therefore, the search for histopatho-
logical predictors of tumor behaviour has thus far been disappointing.
Clinical implications. There are no good determinants to predict tumor recurrence in 
patients after surgical treatment for NFMA, with the exception of follow-up duration, and, 
probably, indicators of postoperative residual tumor. Nonetheless, in our opinion there 







Effect of surgical treatment on visual and endocrine outcome
Improvement of visual dysfunction is the main goal of surgical treatment in pituitary 
macroadenomas by decompression of the optic chiasm. In chapter 3 we showed im-
provement in visual function in ~ 80% of all patients after transsphenoidal surgery, com-
parable with rates reported in other retrospective studies (13;19). The initial event in the 
pathogenesis of decreased visual function in pituitary macroadenomas is compression of 
the optic chiasm. This nerve compression leads to decreased conduction and to demy-
elination (28;29). The improvement of visual dysfunction after surgical treatment, consists 
of two and, probably even three, phases (30). There is an early phase, comprising the 
first hours and days after surgery. In this early, fast phase, the improvement is caused 
by decompression of the visual pathways, leading to a restoration of signal conduction. 
Visual recovery has been demonstrated in the first days after surgical treatment (30;31). 
The phase of delayed recovery is pathophysiologically explained by remyelination of 
the optic nerves. This phase of delayed recovery may even last several years (30;32). It 
is already known that visual acuity improves in the first months after surgical treatment 
(33-37) and that the improvement of visual field defects is a continuing process for at 
least one year (30;32). The contribution of the first phase of recovery might be larger, 
given the fact that more than 50% of the final recovery occurs within the first 3 months 
after surgery (32).
In chapter 4 we have demonstrated that improvement of visual acuity continued also 
until one year after surgical treatment for NFMA. After initial, early post-surgical recovery, 
in the delayed phase a progressive improvement of visual acuity is likely to occur at least 
until one year after transsphenoidal operation. 
Surgical treatment did not reverse pituitary deficiencies in our study (chapter 3). Data 
from other studies concerning postoperative pituitary function are conflicting. Some stud-
ies report, to a variable degree, an improvement in pituitary function (38-42), whereas 
others could not demonstrate significant improvement in pituitary function (13;15;18) or 
even reported a decrease in pituitary function (43;44). 
Clinical implications. Improvement of visual field defects and visual acuity is achieved 
in the majority of patients after surgery for NFMA. The improvement of visual acuity 
continues until one year after surgical treatment. In contrast to visual function, pituitary 
function is not likely to be restored after transsphenoidal surgery. Therefore, the aim of 
surgery should be improvement of visual function, rather than improvement of pituitary 
function.
The role of postoperative radiotherapy
The role of the application of postoperative radiotherapy in patients operated for non-
functioning pituitary macroadenomas is still under debate. Several retrospective studies 
have evaluated the effects of long-term follow-up in unselected, consecutive patients 
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after surgery for NFMA (13;14;18-20;25;45). All these studies have a follow-up period of 
~ 5 years. Recurrence rates in patients without postoperative radiotherapy is reported 
in 11 to 46% of all patients, whereas recurrence rates after postoperative, prophylactic 
radiotherapy ranged between 2-36% during long term follow up. These data suggest that 
postoperative radiotherapy results in a slightly decreased number of recurrences during 
long-term follow-up (20;25). In our series, in 6 patients treated with prophylactic radio-
therapy no tumor recurrence was observed (chapter 3). 
The small benefit of postoperative radiotherapy, i.e. a decrease in long-term recur-
rence rate of NFMA, has to be balanced against potential side effects of radiotherapy. 
Radiotherapy induces increased pituitary deficiencies, a side-effect which is independent 
of tumor recurrence (46-48). Increased mortality is reported in patients with hypopituita-
rism, compared with age-matched controls (49-52). In addition to very rare complications 
of radiotherapy such as optic nerve atrophy and visual deterioration (48;53;54), there 
is about 2.5% cumulative risk of second brain tumors 20 year after radiotherapy (6;55). 
Finally, there are indications that radiotherapy for pituitary adenomas may adversely 
affect quality of life (56). 
In our series without postoperative radiotherapy, long-term tumor control was achieved 
in the absence of recurrence/recurrence in 89% of all patients (chapter 3). Even in the 
case of residual tumor, in 87% of the patients no tumor recurrence was observed. These 
data, observed after six years of follow-up, show that a treatment strategy without postop-
erative radiotherapy is effective and do not justify the routine application of prophylactic 
postoperative radiotherapy in patients with residual tumor after surgery. Moreover, in the 
case of recurrence during long-term follow-up, radiotherapy is still effective to stabilize or 
regress tumor growth (25). With this restrictive treatment strategy, the majority of patients 
will not be exposed to potential long-term sequelae of radiotherapy, whereas in patients 
with recurrences the starting point of radiotherapy is delayed for several years. This is 
an important consideration given the fact that potential side-effects of radiotherapy may 
take years to develop. Nonetheless, postoperative radiotherapy might be considered in 
selected patients with incomplete tumor removal, large residual tumor and panhypopitu-
itarism. Because data concerning the role of ACTH-positive immunostaining as predictor 
for tumor growth are conflicting (19;22;25;57), in our opinion, positive immunostaining 
for ACTH is no indication for postoperative radiotherapy.
Clinical implications. Adequate tumor control can be achieved by transsphenoidal 
surgery for NFMA in the absence of postoperative radiotherapy. This indicates that a 
treatment strategy without postoperative radiotherapy is both effective and safe, and will 
prevent that a large number of patients are exposed to potential long-term sequelae of 








Radiosurgery. The main difference between radiosurgery and conventional radiothera-
py is given by the fact that radiosurgery is given in one large, much focussed, dose, and 
conventional radiotherapy in multiple doses. In theory, the major advantage of radio-
surgery is decreased locoregional irradiation outside the tumor, with increased sparing 
of normal pituitary tissue. This is achieved by the combination of better immobilization 
and high definition 3 dimensional imaging (58). The application of radiosurgery in NFMA 
patients with residual or recurrent disease after surgical treatment, leads to tumor control 
in more than 90% of all patients (59-62). Due to the fact that most patient series have a 
relatively short follow-up period, the long-term effects of radiosurgery on pituitary func-
tion and visual function have not been established. Moreover, long-term results compar-
ing radiosurgery with conventional radiotherapy, both for residual as well as recurrent 
disease, are lacking. 
Medical treatment. Treatment of patients with nonfunctioning macroadenomas with 
dopamine agonists has gained renewed interest, although previous studies using dopa-
mine agonists in these patients have given disappointing results (63-65). Two aspects of 
dopamine therapy account for this renewed interest:
1. The development of cabergoline, which has a longer duration of action, and a higher 
specificity and affinity for the D2-receptor (66)
2. The association of D2-receptor expression with the effect of dopamine agonists in 
nonfunctioning adenomas, both in vitro and in vivo (67).
Recently, Greenman et al. studied the effect of dopamine agonists on nonfunctioning 
adenomas (68). In that study successful treatment was defined as the absence of tumor 
growth, whereas most previous studies used the reduction of tumor volume as marker 
for therapeutic effect (63;64). However, in the absence of visual disturbances, the main 
therapeutic goal is prevention of tumor growth, not necessarily a decrease in tumor vol-
ume. Good tumor control in patients with residual adenoma after initial surgical treatment 
was reported in 90% of patients treated with dopamine agonists, compared with 39% of 
patients without dopamine therapy (68). 
D2-receptor expression was found in 67% of patients operated for NFMA (67). More-
over, the presence of D2-receptor expression was predictive for the effectiveness of 
dopamine agonists (67). These findings implicate that, in selected patients, treatment of 
NFMA with dopamine agonists is possible. However, the role of dopamine agonists has 
to be established in more detail (69). For now, it is unclear whether this treatment is ef-
fective as initial treatment, after surgery in order to prevent recurrence, or after recurrence 
as an alternative for radiotherapy. 
Clinical implications. Radiosurgery has some theoretical advantages and good tumor 
control during short-term follow-up has been reported. D2-receptor expression is a po-
tentially interesting target for cabergoline treatment in NFMA patients. However, the role 
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of both radiosurgery and dopamine agonists in the treatment of NFMA, is not established 
in detail. 
III. FOLLOW-UP STRATEGY AFTER SURGICAL TREATMENT 
Ophthalmologic follow-up
The initial aim of postoperative visual assessment is evaluation of the effects of surgical 
treatment. Improvement of visual function has been shown until one year after surgical 
treatment (30;32) (chapter 4). Follow-up of patients after surgical treatment for pituitary 
macroadenomas should include ophthalmologic assessment within several weeks after 
surgery, but also subsequent assessments after one and two years, in order to estimate the 
final effect of surgical treatment on visual function. These data serve as baseline values 
for potential tumor recurrence in the long-term. 
The role of visual assessment for detection of tumor growth is limited. Although visual 
assessment is a sensitive tool, its use is limitated due to the low negative predictive value. 
In our series tumor growth was accompanied by visual field defects in only half of the 
patients (chapter 2 and 3), comparable with results of other reports (1;2;4). 
Clinical implications. Patients should be informed about the likelihood of prolonged 
improvement of visual function after surgery. Especially in those patients with severe 
compromised visual function, an increase in visual acuity can have dramatic impact on 
social functioning. Because tumor growth is not invariable accompanied by visual field 
defects, assessment of visual function is not a sensitive tool for the detection of tumor 
growth or recurrence. 
Radiological follow-up
The mean reason for post-operative MR imaging is evaluation of the effectiveness of 
surgery. However, after resection of a pituitary tumor, due to packing materials, postop-
erative debris, thickened mucosa and blood, there may be no reduction of tumor seen 
on MR imaging (70). In time, these postoperative features may resolve and the packing 
material may resorb, leading to reduction in tumor volume over months (70). Therefore, 
it is reasonable to assess the effectiveness of surgery 4-6 months after initial surgery. 
In NFMA patients in whom a conservative postoperative approach is chosen, as well as 
in patients after transsphenoidal surgery, the rate of tumor growth can not be predicted 
in individual patients. It is a reasonable approach to repeat MR imaging one year after 
initial diagnosis, in order to make a first estimation of eventual tumor growth. However, 
in chapter 2, the mean increase in diameter was only 0.6 mm/year in patients with tumor 
growth, which is below the detection limit of MRI. These data suggest that, for further 







of possible tumor growth. Moreover, it is important to compare sequential MRI’s with 
the first postoperative MRI, because the increase in tumor volume might be too small to 
detect on subsequent MRI’s. 
Clinical implications. Velocity of tumor (re)growth can not be predicted in individual 
patients after conservative or surgical management for NFMA. In order to discover pa-
tients with rapid tumor grow, a repeat MRI should be performed one year after initial 
diagnosis in patients with a conservative approach, and at 6 months after initial surgical 
treatment in operated patients. During long-term follow-up, a repeat MRI every 2-3 year 
is a safe approach.
IV. LONG-TERM EFFECTS OF TREATMENT FOR NONFUNCTIONING PITUITARY 
MACROADENOMAS 
Quality of life
In 1948, the World health organization defined health not only as the absence of disease, 
but also as the presence of physical, mental and social well-being (71). Quality of Life 
(QoL) assessment is the method to investigate the physical, psychological and social well-
being of the patient. Disease and treatment are being evaluated in terms of the effect on 
physical, psychological and social functioning. The outcomes of these assessments are, 
by definition, influenced by patient’s beliefs, expectations and perceptions (71). This is 
an important consideration because for any given disease the medical point-of-view and 
the patient-point-of-view may not be congruent, especially in chronic diseases (72). QoL 
assessment will enable physicians to provide adequate information about the impact of 
pituitary diseases on patient’s health.
We evaluated QoL in patients treated for NFMA and craniopharyngioma by four vali-
dated health-related questionnaires (HADS, MFI-20, NHP, SF-36), comparing patients 
outcomes to controls groups (chapters 6 and 7). In patients treated for NFMA or cra-
niopharyngioma, QoL is decreased compared with control subjects as well as to age-
adjusted reference values. Compared with our own control values, patients treated for 
NFMA reported a decreased QoL in 18 out of 21 subscales, craniopharyngioma patients 
in 11 out of 21 subscales. This most likely underscores the supposed good health status 
in patient derived controls (73). However, also compared with reference values derived 
from literature, patients treated for NFMA reported a significantly decreased QoL in 10 out 
of 21 subscales and patients treated for craniopharyngioma in 5 out of 21 subscales. 
In both NFMA and craniopharyngioma patients almost all items concerning energy and 
fatigue were affected. Moreover, both patient groups reported reduced physical activity 
and physical mobility and physical functioning. Linear regression analysis revealed the 
presence of multiple pituitary deficiencies (NFMA) and visual impairments (craniopha-
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ryngioma) as the predominant predictors of a decreased QoL. Quality of life was, to a 
lesser extend, also affected by age, female gender, repeat surgery and radiotherapy. In 
patients treated for NFMA, the presence of multiple pituitary deficiencies was the most 
predominant predictor for decreased QoL (chapter 6), pointing towards an important 
role of pituitary function for optimal QoL (56). The effects of hormones in general are 
difficult to quantify at the tissue level. Moreover, hormonal substitution therapy does not 
reproduce the normal plasma hormone profiles of healthy individuals (74). These intrin-
sic imperfections in endocrine replacement therapy may result in subtle physiological 
derangements. Most importantly, this imperfection in endocrine substitution may result 
in a decreased QoL. However, we could not properly assess the effect of hypopituitarism 
per se on QoL, because hypopituitarism was present in 93% of all NFMA patients and in 
all craniopharyngioma patients. 
The 4 health-related questionnaires used in this study, were not disease-specific, i.e. 
they were not developed to assess QoL in NFMA or craniopharyngioma patients, al-
though the NHP is frequently used in patients with pituitary disease. However, we found 
a reduced QoL in the majority of subscales of the MFI-20, the SF-36 and the NHP. This 
seems to point towards a strong overall effect of the pituitary diseases on general health 
and well being, of both the physical and the psychosocial aspects. 
A limitation of the assessment of QoL is that QoL can not be directly measured. It has 
to be measured indirectly by several questions which are supposed to cover a ‘true’ QoL 
(71). Because QoL is not directly measured but inferred from quantitative scoring sys-
tems, it might be possible that the perception of the patient of their QoL is not congruent 
with the quantitative outcomes as measured by QoL questionnaires.
Clinical implications. Despite long-term cure in patients treated for both nonfunction-
ing pituitary adenoma and craniopharyngioma, QoL is significantly reduced compared 
with a healthy population, especially in the physical items and items concerning energy 
(chapter 6 and 7). These irreversible effects of these pituitary diseases have to be taken 
into account by doctors in the assessment of these patients. 
Mortality in patients with pituitary adenomas
A number of studies have reported increased mortality in patients with pituitary tumors 
(49;75-79) and associated conditions such as hypopituitarism (50-52). In the majority of 
studies the general population was used as control group to assess mortality in pituitary 
adenomas. However, it is presently unknown to what extent the excess mortality is 
caused by pituitary tumors and their treatment in general, and to what extent by (previ-
ous) exposure to cortisol or growth hormone (GH) overproduction. 
In chapter 5 we evaluated mortality rates during long-term follow up of patients with 
pituitary adenomas treated by transsphenoidal surgery. Because mortality in pituitary 







morbidity, we compared mortality in patients with Cushing’s disease and acromegaly 
to mortality in patients treated for NFMA. Patients treated for NFMA lack the morbidity 
conditions specific for acromegaly or Cushing’s disease. 
The increased mortality in operated patients with pituitary adenomas is associated with 
several factors, some of which are associated with pituitary tumors in general and some 
of which are disease specific. Transsphenoidal surgery is associated with a perioperative 
mortality of ~ 0.9% (80;81). Hypopituitarism, present in the majority of patients treated for 
pituitary macroadenomas, is associated with increased mortality (51;52). Several studies 
reported increased cardiovascular and cerebrovascular mortality in patients with pituitary 
diseases other than acromegaly and Cushing’s disease (50;52;77-79). Although the exact 
mechanisms by which hypopituitarism is causing increased mortality are unclear, there 
are suggestions that hypopituitarism is associated with vascular disease (50;82-84). Sev-
eral authors point towards the role of untreated GH-deficiency in this respect (50;85). 
Cortisol excess induces central obesity, diabetes mellitus and hypertension (86). These 
effects are reversed upon cure of Cushing’s disease. However, it has been suggested 
that cortisol overproduction is associated with increased cardiovascular risk, continuing 
even after remission of the disease (87;88). Therefore, the effects of transient cortisol 
overproduction may not be reversible with respect to certain biological properties that 
influence mortality. 
The mortality rate for the whole cohort in our study was increased by 41%, compared 
with the general population, despite adequate treatment (chapter 5). In addition, the 
mortality risks appeared to be different among the three pituitary diseases. The standard-
ized mortality ratio (SMR) in NFMA patients was 1.24 (95% CI 0.82-1.74). In patients with 
Cushing’s disease the SMR was 2.39 (95% CI 1.22-3.9). Moreover, after transsphenoidal 
surgery for Cushing’s disease there is an increased mortality risk compared with both 
NFMA and acromegaly. This points towards cortisol effects on increased mortality in 
patients with Cushing’s disease, because treatment and medical care were comparable 
between patients with Cushing’s disease and both patients with NFMA or acromegaly. 
Moreover, it implies that previous, transient overexposure to cortisol is associated with 
increased mortality, despite long term normalisation of cortisol levels in the majority of 
patients. The importance of cortisol in mortality excess is established by the fact that 
mortality is increased in patients with persistent disease, compared with cured patients 
(89;90). 
Clinical implications. The relative mortality risk is increased in patients with Cush-
ing’s disease compared with both NFMA and acromegaly. This implicates that exposure 
to cortisol excess is a major contributor of the increased mortality even after cure of 
Cushing’s disease.
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In dit proefschrift hebben we de effecten geëvalueerd van zowel behandeling, als van 
lange termijn follow-up bij patiënten, behandeld voor een niet-functionerend hypofyse 
macroadenoom (NFMA). Alle patiënten werden behandeld en vervolgd in het Leidsch 
Universitair Medisch Centrum. In deze algemene discussie zullen de volgende aspecten 
aan de orde komen:
• Natuurlijk beloop en groei van niet-functionerende hypofyse macroadenomen
• Behandeling van niet-functionerende hypofyse macroadenomen
• Follow-up strategieën na chirurgische behandeling
• Lange termijn effecten van behandeling voor niet-functionerende hypofyse macro-
adenomen
I. NATUURLIJK BELOOP EN GROEI VAN NIET-FUNCTIONERENDE HYPOFYSE 
MACROADENOMEN
Het natuurlijke beloop van hypofyseadenomen
Het natuurlijke beloop van NFMA’s is voor een belangrijk deel onbekend omdat het meren-
deel van de patiënten met een NFMA geopereerd wordt. Het primaire doel van de studie, 
zoals in hoofdstuk 2 beschreven, was dan ook het natuurlijk beloop van NFMA in kaart 
te brengen. In deze studie, bestaande uit 28 patiënten, met een gemiddelde follow-up van 
meer dan 7 jaar, werd bij 50% van de patiënten groei van het NFMA gezien. De incidentie 
van groei van NFMA is iets hoger dan gerapporteerd in eerdere studies, die een tumorgroei 
bij ongeveer 25% van alle niet-geopereerde NFMA patiënten laten zien (1-4). De langere 
follow-up duur, evenals het verschil in methode om het tumorvolume te meten, kunnen ten 
grondslag liggen aan het hogere percentage patiënten met tumorgroei in onze studie.
Bij patiënten met een hypofyse microadenoom wordt slechts bij een klein deel van de 
patiënten tumorgroei gezien. De kans op tumorgroei bij deze patiënten is ongeveer even 
groot als de kans op afname in tumor volume (2;4). Dit gegeven is in overeenstemming 
met het feit dat in grote autopsie-series het vóórkomen van macroadenomen zeldzaam is 
(5). Daarentegen heeft bij patiënten met een NFMA de tumor reeds aangetoond te kun-
nen groeien. Het is opvallend dat in onze studie (hoofdstuk 2) een spontane reductie in 
tumorvolume werd gezien bij 29% van alle patiënten gedurende follow-up, terwijl in 21% 
er geen verandering in tumorvolume werd waargenomen. 
Klinische implicaties. NFMA’s leiden niet in alle gevallen tot een toename in tumor 
volume gedurende follow-up. Zelfs indien sprake is van tumorgroei, is er een grote indi-
viduele variabiliteit. Daarnaast kan een NFMA spontaan in volume afnemen. Dit betekent 









Het zou een groot voordeel betekenen om in individuele patiënten die zich met een 
NFMA presenteren, tumorgroei te kunnen voorspellen. Dit zou immers een geïndividuali-
seerde strategie voor behandeling en follow-up mogelijk maken. In onze studie (hoofd-
stuk 2 en 3) hebben we gezocht naar voorspellers en determinanten voor tumorgroei bij 
patiënten met een NFMA. In het geval van een conservatief beleid kunnen alleen klinisch 
kenmerken worden gebruikt, bij geopereerde patiënten kunnen naast klinische-, ook 
histopathologische kenmerken worden gebruikt om tumorgroei te voorspellen. 
In de niet-geopereerde patiëntenserie (hoofdstuk 2), bleken geen onafhankelijke 
voorspellers voor toename of afname in tumorvolume aantoonbaar. De regressie analyse 
werd uitgevoerd in een model met toename en afname van tumorvolume als afhankelijke 
variabelen, en leeftijd, geslacht, tumorvolume, tumorextensie, hypopituitarisme, prolac-
tine-spiegels en duur van follow-up als onafhankelijke variabelen.
Klinische implicaties. In niet-geopereerde patiënten met een NFMA blijken geen 
goede parameters voorhanden die afname of toename van tumor volume in individuele 
patiënten kunnen voorspellen.
Apoplexie
Hypofysaire apoplexie is een zeldzame, maar potentieel levensbedreigende (6), compli-
catie van hypofysetumoren. Het wordt veroorzaakt door infarcering dan wel bloeding van 
de tumor (7). De geschatte prevalentie van apoplexie bij patiënten met hypofyse tumoren 
is minder dan 1% (4). In een groep met ongeselecteerde NFMA patiënten, is apoplexie 
het presenterende symptoom bij ongeveer 20% van alle patiënten (8) (hoofdstuk 3).
De optimale behandelstrategie bij NFMA patiënten met apoplexie is onderwerp van 
discussie (9-11). Omdat bijnierinsufficiëntie kan bestaan, moet direct met toedienen van 
corticosteroïden worden gestart (10;11). Bij patiënten met ernstige visuele disfunctie is een 
spoedoperatie geïndiceerd. Na transsfenoidale operatie verbeteren gezichtsvelddefecten 
en visusstoornissen in het merendeel van de patiënten (9-11). Een conservatieve bena-
dering met zorgvuldige follow-up bij geselecteerde patiënten met apoplexie zonder, of 
met slechts milde oogafwijkingen, is een goede behandeloptie, zonder nadelige effecten 
(9;12). We beschreven 4 NFMA patiënten die zich met apoplexie presenteerden (hoofd-
stuk 2). Bij 3 van deze patiënten ging de apoplexie gepaard met gezichtsvelddefecten. 
In al deze 3 patiënten verbeterden de gezichtsvelden spontaan binnen 3 maanden. Bij 1 
van de 4 patiënten was er hypofyse uitval van 3 assen, inclusief de hypofyse-bijnieras. In 
deze patiënt verbeterde de hypofysefunctie spontaan binnen enkele maanden. 
Klinische implicaties. Een afwachtend beleid met zorgvuldige observatie en follow-
up is een veilige initiële behandelstrategie bij geselecteerde NFMA patiënten die zich met 
apoplexie presenteren. 
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II. BEHANDELING VAN NIET-FUNCTIONERENDE HYPOFYSEADENOMEN
Indicaties voor chirurgische behandeling
Niet-functionerende hypofyse microadenomen veroorzaken in het algemeen geen klach-
ten of symptomen. Omdat microadenomen de anatomische grenzen van de sella turcica 
niet overschrijden, veroorzaken ze geen gezichtsvelddefecten. Daarnaast is de kans op 
groei van de tumor bijna even groot als de kans op afname van het tumor volume (2;4). 
Dit aspect onderstreept de visie dat bij patiënten met niet-functionerende microadeno-
men een ‘wait-and-see’ beleid aangewezen is.
Hypofyse macroadenomen induceren vaak gezichtsvelddefecten en hypofyse insuf-
ficiëntie (13-15). Transsfenoidale operatie is de hoeksteen in de behandeling van NFMA. 
Het belangrijkste doel van de behandelstrategie bij patiënten met NFMA is het herstel van 
visuele functie and adequate lange-termijn tumorcontrole. Omdat hypofyse macroade-
nomen niet in alle gevallen verder groeien, is visuele disfunctie de voornaamste indicatie 
voor chirurgische therapie. 
De optimale behandeling van patiënten met een NFMA zonder gezichtsvelddefecten 
is niet geheel uitgekristalliseerd (3;16;17). Echter, meer precieze kennis van het natuur-
lijk beloop van NFMA’s zou tot een selectie van patiënten kunnen leiden waarbij een 
expectatief beleid geïndiceerd is. In onze serie van 28 patiënten, was bij 14 sprake van 
tumorgroei tijdens follow-up (hoofdstuk 2). Slechts bij 6 patiënten ging de tumorgroei 
gepaard met gezichtsvelddefecten. Deze 6 patiënten werden geopereerd omdat gezichts-
velddefecten een harde operatie-indicatie vormen. Dit betekent dat, na ruim 7 jaar fol-
low-up, bij slechts 21% van de initiële patiëntengroep chirurgie geïndiceerd was. In alle 
6 gevallen verbeterden de visuele defecten na operatie. Onze studie laat zien dat in het 
geval zich gezichtsvelddefecten ontwikkelen tijdens een conservatieve behandelstrategie, 
het effect van chirurgie nog steeds heel goed is. 
Klinische implicaties. De voornaamste indicatie voor chirurgie bij patiënten met een 
NFMA is gezichtsvelddefecten. In de afwezigheid van visusproblemen is een expectatief 
beleid bij geselecteerde NFMA patiënten een veilig alternatief, omdat in ruim 75% van de 
patiënten geen chirurgisch ingrijpen noodzakelijk blijkt. 
Effect van transsfenoidale chirurgie op tumorrecidief tijdens langdurige follow-up
In hoofdstuk 3 hebben we het beloop van NFMA na transsfenoïdale operatie beschre-
ven. In dit onderzoek werden 97 opeenvolgende patiënten ruim 6 jaar na transsfenoidale 
operatie gevolgd. Bij 6 van deze patiënten werd postoperatieve radiotherapie gegeven. 
Bij slechts 10% van de patiënten trad een tumorrecidief op, gemiddeld 6,3 jaar na de 
initiële operatie (range 3-11 jaar). Bij patiënten met residuaal tumorweefsel op de post-







75% (zie figuur 1). Bij patiënten zonder residuaal tumorweefsel waren deze percentages 
respectievelijk 100% en 100%. 
Onze studie laat zien dat 10 jaar na de chirurgische behandeling, slechts bij 20% van 
alle NFMA patiënten een tumorrecidief is opgetreden. Echter, in het geval van tumor-
recidief, is er sprake van een grote individuele variabiliteit (hoofdstuk 3). Dit is in 
overeenstemming met de grote variabiliteit in niet-geopereerde patiënten (hoofdstuk 2). 
Omdat de follow-up in de meeste onderzoeken naar NFMA patiënten na transsfenoidale 
operatie beperkt is tot ongeveer 6 jaar, is het mogelijk dat verlenging van de follow-up 
duur hogere recidief percentages zal laten zien. In dit opzicht is een studie van Breen et 
al. interessant (6). In een studie met geopereerde en bestraalde NFMA patiënten laten 
zij een 10, 20 en 30 jaars recidief vrije overleving van respectievelijk 88%, 78% and 65% 
zien. Dit impliceert dat er geen afname in de kans op tumorrecidief lijkt te zijn, zelfs niet 
30 jaar na initiële behandeling. 
Klinische implicaties. Transsfenoidale chirurgie zonder postoperatieve radiotherapie 
geeft goede tumor controle bij patiënten met een NFMA, ook tijdens lange follow-up. 
Indien bij individuele patiënten met een NFMA toch postoperatieve radiotherapie wordt 
overwogen, moet in het achterhoofd worden gehouden dat slechts een klein percentage 
van de patiënten een recidief zal ontwikkelen. 
Figuur 1. Kaplan Meier curve voor recidiefvrije overleving bij patiënten met en patiënten zonder residu 
tumor na transsfenoidale operatie
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Determinanten en voorspellers voor tumorrecidief na operatieve behandeling
De determinanten voor tumorrecidief bij NFMA patiënten zijn voor een belangrijk deel 
onbekend. Om die reden hebben we gekeken naar voorspellers en determinanten van 
tumor recidief na chirurgie. In onze studie bij geopereerde NFMA patiënten was de enige 
determinant voor tumorrecidief de follow-up duur (hoofdstuk 3). Geslacht, profylacti-
sche radiotherapie, positieve immunohistochemie voor hypofysaire hormonen, positieve 
immunohistochemie voor ACTH, and parasellaire/infrasellaire tumor extensie waren geen 
onafhankelijke predictoren voor tumorgroei. 
Het is redelijk om te veronderstellen dat tumor recidieven vaker voorkomen bij pa-
tiënten met een incomplete tumorresectie. Dit is per definitie het geval bij alle patiënten 
met parasellaire of infrasellaire tumorexpansie (18). In verschillende onderzoeken is een 
verband aangetoond tussen de aanwezigheid van residuaal tumorweefsel op de MRI en 
de kans op een tumorrecidief (19;20). In onze studie wees statistische analyse eveneens 
in de richting van tumorresidu als onafhankelijke voorspeller voor recidief, hoewel deze 
associatie niet significant was (p=0.1). 
De methoden om een inschatting van de aanwezigheid van residuaal tumorweefsel te 
maken zijn imperfect. De beoordeling van de chirurg met betrekking residuaal weefsel 
geeft een onderschatting van het aantal patiënten met tumor residu (19). Daarnaast blijkt 
bij microscopische onderzoek durale invasie aanwezig te zijn bij 94% van alle patiënten 
met een macroadenoom met suprasellaire extensie (21). Dit onderstreept het feit dat ook 
de postoperatieve MRI de aanwezigheid van tumor residu kan onderschatten. 
De klinische betekenis van positieve immunohistochemie voor ACTH is onderwerp 
van discussie. Sommige auteurs suggereren een agressiever beloop bij patiënten met een 
ACTH-positieve NFMA en adviseren daarom postoperatieve radiotherapie bij deze pa-
tiënten (22-24). Daarentegen is een toename van tumorrecidieven bij patiënten met een 
ACTH-positieve immunohistochemie niet aangetoond in een aantal studies (19;22;25), 
evenmin als in onze studie (hoofdstuk 3). 
Hoewel DNA-ploiditeit vaak wordt gebruikt om een onderscheid te maken tussen 
benigne en maligne tumoren, blijkt dit geen goede predictor voor tumorgroei bij NFMA 
te zijn (26). Daarnaast werd geen goede correlatie gevonden tussen histologische prolife-
ratie-markers voor apoptose en tumor recidieven (27) evenmin als tussen kern-atypie en 
tumor groei (26). Er is een correlatie beschreven tussen Ki-67, een marker voor celprolife-
ratie, en tumor invasie, hoewel dit niet in alle studies bevestigd wordt (24). De zoektocht 
naar histopathologische predictoren voor tumorgroei is, tot dusver, teleurstellend. 
Klinische implicaties. Er blijken geen goede determinanten te zijn die tumorrecidief 
kunnen voorspellen na chirurgische behandeling voor een NFMA, met de uitzondering 
van follow-up duur en mogelijk determinanten van postoperatief tumorresidu. Dit be-








Effect van chirurgische behandeling op visuele en endocriene functie
Verbetering van visuele disfunctie door opheffen van de chiasma compressie, is het be-
langrijkste doel van chirurgische behandeling van niet-functionerende hypofyse macro-
adenomen. In hoofdstuk 3 hebben we verbetering van visuele functie bij ~ 80% van alle 
patiënten na transsfenoidale chirurgie laten zien, een percentage dat vergelijkbaar is met 
andere studies (13;19). Compressie van het chiasma opticum is het eerste event in de 
pathogenese van verminderde visuele functie door macroadenomen. Deze zenuwcom-
pressie leidt tot een verminderde conductie en demyelinisatie (28;29). De verbetering van 
de visuele functie na operatie berust op twee, mogelijk drie fases (30). 1) De eerste fase 
begint de eerste uren en dagen na operatie. Tijdens deze eerste fase wordt de verbetering 
veroorzaakt door decompressie van het visuele geleidingssysteem, waardoor een herstel 
van de signaaltransductie optreedt. Herstel van de visuele functie is aangetoond in de 
eerste dagen na operatie (30;31). 2) De fase van het vertraagd herstel wordt pathofysio-
logisch verklaard door de remyelinisatie van de zenuwbanen. Deze vertraagde fase kan 
meerdere jaren in beslag nemen (30;32). Het is bekend dat gezichtsscherpte in de eerste 
maanden na de operatie verbetert (33-37) en dat verbetering van gezichtsvelddefecten 
een proces is dat langer dan een jaar kan duren (30;32). De bijdrage aan het herstel van 
de visus van de eerste fase is waarschijnlijk groter, gegeven het feit dat meer dan 50% 
van het uiteindelijke herstel optreedt binnen drie maanden na chirurgische behandeling 
(32).
In hoofdstuk 4 hebben we aangetoond dat ook verbetering van visus een continu 
proces is, tot in ieder geval 1 jaar na operatie voor NFMA. Na initiële, postoperatieve 
verbetering, wordt tijdens de late fase een progressieve verbetering van gezichtsscherpte 
gezien tot ten minste een jaar na de transsfenoidale ingreep. 
Chirurgische behandeling liet geen verbetering van hypofyse functies zien in onze 
studie (hoofdstuk 3). Gegevens van andere studies betreffende het eventuele herstel 
van hypofysefunctie door operatie, laten tegenstrijdige resultaten zien. Sommige studies 
vermelden, in wisselende mate, een verbetering van hypofyse functie (38-42), terwijl an-
dere studies geen verbetering (13;15;18) of zelfs een verslechtering van hypofyse functies 
tonen (43;44). 
Klinische implicaties. Verbetering van gezichtsvelden en gezichtsscherpte wordt 
bereikt in het merendeel van de NFMA patiënten na chirurgische behandeling. De ver-
betering van gezichtsscherpte is een continu proces dat ten minste een jaar na operatie 
nog doorgaat. In tegenstelling tot de visuele functie, is het niet waarschijnlijk dat de hy-
pofysefunctie herstelt door transsfenoidale chirurgie van macroadenomen. Het doel van 
operatie bij NFMA’s is dan ook het herstel van visuele functie, niet van hypofysefunctie. 
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De rol van postoperatieve radiotherapie
Over de rol van postoperatieve radiotherapie bij geopereerde NFMA patiënten bestaat 
nog steeds discussie. Verschillende retrospectieve studies hebben gekeken naar de lange-
termijn effecten in ongeselecteerde, opeenvolgende NFMA patiënten na transsfenoidale 
chirurgie (13;14;18-20;25;45). Al deze studies hebben een follow-up van ~ 5 jaar. Tumor-
recidief bij patiënten zonder postoperatieve radiotherapie wordt gerapporteerd in 11 tot 
46% van alle patiënten, terwijl het recidiefpercentage bij patiënten met postoperatieve 
radiotherapie varieert tussen de 2 en 36%. Deze data suggereren dat postoperatieve 
radiotherapie resulteert in een kleine afname van het recidiefpercentage tijdens lange-
termijn follow-up (20;25). In ons onderzoek werd bij de 6 patiënten met postoperatieve 
radiotherapie geen tumorrecidief gezien (hoofdstuk 3). 
Het voordeel van postoperatieve radiotherapie, te weten de mogelijke afname van 
tumorrecidieven tijdens lange follow-up, moet worden afgewogen tegen de potentiële 
bijwerkingen van radiotherapie. Radiotherapie induceert een toename van hypofyse 
insufficiënties (46-48). Een verhoogde mortaliteit is gevonden bij patiënten met hypop-
ituitarisme in vergelijking met leeftijds-gematchte controles (49-52). Naast zeer zeldzame 
complicaties van radiotherapie als atrofie van de nervus opticus en vermindering van 
visuele functies (48;53;54), is er een 2.5% cumulatief risico op het krijgen van secundaire 
hersentumoren 20 jaar na radiotherapie (6;55). Ten slotte zijn er indicaties dat radiothe-
rapie een negatief effect op de kwaliteit van leven heeft (56). 
In ons onderzoek, bij patiënten zonder postoperatieve radiotherapie, werd een goede 
lange-termijn tumor-controle bereikt in 89% van alle patiënten (hoofdstuk 3). Zelfs bij 
patiënten met tumorresidu op de postoperatieve MRI, werd bij 87% van de patiënten geen 
tumorrecidief gezien. Deze data, met een follow-up duur van 6 jaar, laten zien dat een 
behandelstrategie zonder postoperatieve radiotherapie effectief is en het toepassen van 
postoperatieve radiotherapie niet zonder meer rechtvaardigt. Daarnaast blijkt in het geval 
van een tumorrecidief radiotherapie nog steeds te leiden tot tumorregressie of tumorsta-
bilisatie (25). Met deze restrictieve behandelstrategie, zal het merendeel van de patiënten 
niet worden blootgesteld aan de potentiële lange-termijn bijwerkingen van radiotherapie, 
terwijl in het geval van een tumorrecidief het startpunt van de radiotherapie met een 
aantal jaar wordt uitgesteld. Dit laatste is een belangrijke overweging, gegeven het feit dat 
potentiële bijwerkingen van radiotherapie pas na vele jaren optreden. Bij geselecteerde 
patiënten, indien er sprake is van panhypopituitarisme en een groot tumorresidu, kan 
radiotherapie worden overwogen. Omdat data aangaande de betekenis van ACTH posi-
tieve immunohistochemie voor tumorrecidief niet eensluidend zijn, (19;22;25;57), is het 
onze opinie dat ACTH-positieve immunohistochemie geen indicatie voor profylactische 
radiotherapie vormt.
Klinische implicaties. Adequate tumorcontrole wordt verkregen door transsfenoidale 







delstrategie zonder postoperatieve radiotherapie veilig en effectief is, en voorkomt dat 
een groot aantal patiënten wordt blootgesteld aan de negatieve lange-termijn effecten 
van radiotherapie, zonder dat hier een duidelijk voordeel tegenover staat. 
Nieuwe behandelingen
Radiochirurgie. Het voornaamste verschil tussen radiochirurgie en conventionele ra-
diotherapie is dat radiochirurgie wordt gegeven in een grote, gefocuste dosis, terwijl 
conventionele radiotherapie wordt toegediend in multipele dosis. In theorie is het grote 
voordeel van radiochirurgie de verminderde locoregionale stralingsbelasting in weef-
selgebieden buiten de tumor, waarbij het normale hypofyseweefsel in belangrijke mate 
gespaard wordt. Dit wordt bereikt door een combinatie van betere immobilisatie en 
high definition 3 dimensionale beeldvorming (58). De toepassing van radiochirurgie bij 
patiënten met een NFMA en residuaal tumorweefsel of recidief tumor, leidt bij 90% van de 
patiënten tot adequate tumor controle (59-62). Omdat in deze onderzoeken de follow-up 
duur relatief kort is, zijn de lange termijn effecten van radiochirurgie op hypofyse- en 
visuele functie nog niet duidelijk. Daarnaast zijn, zowel bij patiënten met tumor residu als 
bij patiënten met tumorrecidief, geen lange-termijn resultaten bekend die radiochirurgie 
met conventionele radiotherapie vergelijken. 
Medicamenteuze behandeling. Behandeling van NFMA patiënten met dopamine-
agonisten staat recent weer in de belangstelling, ondanks het feit dat resultaten van 
dopamine-agonisten in eerdere studies teleurstellend waren (63-65). Twee aspecten van 
de dopamine-agonisten therapie dragen bij aan deze hernieuwde belangstelling:
1. De ontwikkeling van cabergoline, een dopamine-agonist met een langere werkings-
duur en een hogere specificiteit en affiniteit voor de D2-receptor (66)
2. De associatie van de D2-receptor expressie met het effect van dopamine-agonisten, 
zowel in vivo als ook in vitro (67).
Recent hebben Greenman et al. de effecten of dopamine agonisten bij NFMA’s bestu-
deerd (68). In deze studie werd succesvolle behandeling gedefinieerd als de afwezigheid 
van tumor groei, daar waar veel eerdere studies de reductie van tumor volume als marker 
voor therapeutisch effect gebruikten (63;64). In de afwezigheid van visusproblemen is 
echter het primaire therapeutische doel de preventie van tumorgroei, niet noodzakelijk 
de afname van tumorvolume. Goede tumorcontrole bij patiënten met een recidief ade-
noom na initiële chirurgische therapie wordt gerapporteerd bij 90% van de met dopamine 
agonisten behandelde patiënten, vergeleken met 39% van de patiënten die niet met 
dopamine agonisten werden behandeld (68). 
D2-receptor expressie werd gevonden bij 67% van geopereerde patiënten met een 
NFMA (67). Tevens bleek de aanwezigheid van D2-receptor expressie voorspellend voor 
het effect van dopamine agonisten (67). Deze bevindingen impliceren dat, bij geselec-
teerde patiënten, behandeling van een NFMA met dopamine agonisten mogelijk effectief 
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is. De plaats van dopamine agonisten bij de behandeling van NFMA’s moet nog verder 
uitkristalliseren (69). Zo is het onduidelijk of deze behandeling effectief is als initiële 
behandeling, na chirurgie om recidieven te voorkomen, of na tumorrecidief als een alter-
natief voor radiotherapie. 
Klinische implicaties. Radiochirurgie heeft enkele theoretische voordelen en goede 
korte termijn resultaten zijn beschreven. D2-receptor expressie is een potentieel interes-
sant target voor therapie met dopamine agonisten. Echter, de rol van zowel radiochirurgie 
als ook dopamine agonisten bij de behandeling van NFMA, moet nog nader worden 
onderzocht en uitgewerkt. 
III. FOLLOW-UP STRATEGIE NA CHIRURGISCHE BEHANDELING 
Oogheelkundige follow-up
Het initiële doel van postoperatieve beoordeling van de visuele functie is de evaluatie 
van het effect van chirurgie. Verbetering van visuele functie is aangetoond tot een jaar na 
operatie (30;32) (hoofdstuk 4). Follow-up van patiënten na chirurgie voor hypofysaire 
macroadenomen moet in ieder geval oogheelkundige beoordeling binnen enkele weken 
omvatten, maar tevens beoordeling na 1 en 2 jaar, om het uiteindelijke effect van chi-
rurgische behandeling op visus te kunnen beoordelen. Deze data dienen dan tevens als 
uitgangswaarde voor potentiële tumor recidieven tijdens langere follow-up. 
De rol van oogheelkundig onderzoek voor de detectie van tumorrecidieven is beperkt. 
Hoewel beoordeling van gezichtsvelden een sensitieve methode is, wordt de rol beperkt 
door de lage negatief voorspellende waarde. In onze onderzoeken ging tumorgroei in 
slechts de helft van de patiënten gepaard met gezichtsvelddefecten (hoofdstuk 2 en 3), 
een percentage vergelijkbaar met resultaten uit andere studies. (1;2;4). 
Klinische implicaties. Patiënten moeten worden geïnformeerd over de mogelijkheid 
van een langer durende herstelperiode voor de visus na chirurgie. Dit is van belang om-
dat een verminderde gezichtsscherpte een grote impact op de kwaliteit van leven heeft. 
Omdat tumorgroei niet altijd vergezeld gaat met gezichtsvelddefecten, is beoordeling van 
gezichtsvelden geen sensitieve methode om tumorgroei op het spoor te komen. 
Radiologische follow-up
De voornaamste reden voor een postoperatieve MRI is het beoordelen van het effect van 
de chirurgische interventie. Men dient zich bewust te zijn dat een eerste postoperatieve 
MRI, ten gevolge van postoperatieve debris, verdikte mucosa en bloed, mogelijk geen 
reductie in tumor volume laat zien (70). Deze postoperatieve veranderingen verdwijnen 
meestal binnen drie maanden (70). Daarom is het zinnig de eerste MRI na een operatie 







Bij NFMA patiënten bij wie is gekozen voor een conservatief beleid, evenals bij pa-
tiënten na transsfenoidale chirurgie, kan, in individuele gevallen, de snelheid van tumor 
groei niet goed worden voorspeld. Het is een rationele benadering om een eerste MRI 
te herhalen na 1 jaar, ten einde een inschatting te maken van de eventuele snelheid van 
tumorgroei. We hebben echter in hoofdstuk 2 laten zien dat de gemiddelde toename 
in diameter bij patiënten met tumorgroei slechts 0.6 mm/jaar was, hetgeen onder de 
detectiegrens van de MRI ligt. Deze data suggereren dat voor verdere follow-up, een 
beleid waarbij de MRI elke 2-3 jaar wordt herhaald veilig en optimaal is voor de detectie 
van tumorgroei. Daarnaast is het belangrijk om bij opeenvolgende MRI’s steeds de eerste 
(postoperatieve) MRI bij de beoordeling te betrekken, omdat de toename in tumorvo-
lume te klein kan zijn om op opeenvolgende MRI’s goed in te schatten. 
Klinische implicaties. De snelheid van tumorgroei kan, bij individuele patiënten niet 
goed worden voorspeld, zowel na chirurgie als bij een conservatief beleid van NFMA’s. 
Om patiënten met een snelle tumorgroei op te sporen moet een MRI worden herhaald 
1 jaar na diagnose bij patiënten met een conservatief beleid, en 6 maanden na operatie 
bij geopereerde patiënten. Gedurende de follow-up is het raadzaam de MRI elke 2-3 jaar 
te herhalen. 
IV. LANGE-TERMIJN EFFECTEN VAN BEHANDELING VOOR NIET-FUNCTIONERENDE 
HYPOFYSE MACROADENOMEN 
Kwaliteit van leven
In 1948 werd door de World Health Organization gezondheid niet alleen gedefinieerd als 
de afwezigheid van ziekte, maar tevens als de aanwezigheid van fysiek, geestelijk en so-
ciaal welbevinden (71). Kwaliteit van leven (KvL) assessment is een methode om fysiek, 
geestelijk en sociaal welbevinden van de patiënt te onderzoeken. Ziekte en behandeling 
worden geëvalueerd in termen van om fysiek, geestelijk en sociaal welbevinden. De 
uitkomsten van dergelijke onderzoekingen worden per definitie beïnvloed door de over-
tuigingen, verwachtingen en percepties van de patiënt (71). Dit is een belangrijke over-
weging omdat, voor een willekeurige ziekte, het medische gezichtspunt kan verschillen 
van het gezichtspunt van de patiënt (72). KvL onderzoek maakt het voor artsen mogelijk 
om adequate informatie te verkrijgen over de impact van hypofyse ziekten.
We hebben KvL geëvalueerd bij patiënten die zijn behandeld voor NFMA en craniofa-
ryngiomen middels 4-gevalideerde en ziekte gerelateerde vragenlijsten (HADS, MFI-20, 
NHP, SF-36), waarbij we de patiënten vergeleken met gezonde controles (hoofdstuk 
6 en 7). Bij patiënten die werden behandeld voor NFMA of een craniofaryngioom, is 
de KvL duidelijk afgenomen in vergelijking met controlegroepen. In vergelijking met 
eigen controle patiënten rapporteerden NFMA patiënten een verminderde KvL in 18 
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van de 21 subschalen, craniofaryngioom patiënten in 11 van de 21 subschalen. Ook in 
vergelijking met literatuurcontroles, laten NFMA patiënten (in 10 van de 21 subschalen) 
en craniofaryngioom patiënten (5 van de 21 subschalen) een verminderde KvL zien. Dit 
onderstreept de veronderstelde goede gezondheidsstatus bij controles die door patiënten 
zijn verzameld (73).
Bij zowel NFMA alsook craniofaryngioom patiënten zijn alle items die betrekking heb-
ben op energie en vermoeidheid afwijkend (hoofdstuk 6 en 7). Daarnaast wordt in 
beide patiëntengroepen een verminderde fysieke activiteit, mobiliteit en functioneren 
gevonden. Lineaire regressie analyse toont de aanwezigheid van multipele hypofysaire 
deficiënties (NFMA) en verminderde visus (craniofaryngioom) als de voornaamste predic-
toren voor een verminderde KvL. KvL wordt, in mindere mate, tevens negatief beïnvloed 
door leeftijd, vrouwelijk geslacht, multipele chirurgische procedures en radiotherapie. De 
aanwezigheid van multipele hypofysaire insufficiëntie als predictor voor een verminderde 
KvL (hoofdstuk 6), wijst in de richting van de belangrijke rol van de hypofyse functie 
voor een optimale KvL (56). De intrinsieke imperfecties van hormonale substitutiethe-
rapie kunnen leiden tot subtiele fysiologische ontregelingen en daarmee ten grondslag 
liggen aan de verminderde KvL door hypofyse deficiënties (74). 
De 4 ziekte-gerelateerde vragenlijsten die we in de studies hebben gerbuikt, zijn niet 
ziekte-specifiek. Met andere woorden: de vragenlijsten zijn niet ontwikkeld om KvL te 
evalueren bij NFMA of cranyofaringoom patiënten, hoewel de NHP vaak gebruikt wordt 
bij patiënten met hypofyse ziekten. Desondanks vonden we een verminderde KvL in de 
meerderheid van de subschalen van de MFI-20, de SF-36 en de NHP. Dit lijkt te wijzen op 
een groot effect van de hypofyse op algemene gezondheid en welbevinden, zowel voor 
wat betreft het fysieke alsook het psychosociale aspect. 
Een beperking van het onderzoek is dat KvL niet direct kan worden gemeten. Het 
wordt afgeleid uit meerdere vragen die geacht worden het begrip kwaliteit van leven te 
dekken (71). Omdat KvL niet direct gemeten wordt, maar afgeleid middels kwantitatieve 
scoringssystemen, blijft het mogelijk dat de perceptie van de patiënt betreffende zijn/haar 
KvL niet overeenkomt met de kwantitatieve uitkomstmaten zoals uit de vragenlijsten naar 
voren komen. 
Klinische implicaties. Ondanks lange-termijn curatie bij patiënten met NFMA en 
craniofaryngioom is er een duidelijk verminderde kwaliteit van leven bij deze groep 
patiënten in vergelijkingen met de algemene bevolking (hoofdstuk 6 en 7). Dit geldt 
met name voor fysieke- en vermoeidheidsaspecten. Deze irreversibele effecten van hy-
pofysaire ziekten moeten in ogenschouw worden genomen door artsen bij beoordeling 







Mortaliteit bij patiënten met hypofyseadenomen 
Verschillende studies hebben een verhoogde mortaliteit aangetoond bij patiënten met 
hypofysetumoren (49;75-79) en geassocieerde condities zoals hypopituitarisme (50-52). 
In het merendeel van de studies is de algemene bevolking gebruikt als controlegroep. 
In hoofdstuk 5 hebben we gekeken naar de mortaliteitcijfers bij patiënten na trans-
sfenoidale operatie voor hypofysetumoren. Omdat mortaliteit geassocieerd is met zowel 
algemene aspecten van hypofysetumoren als ook met ziekte specifieke aspecten, heb-
ben we de mortaliteit bij patiënten met de ziekte van Cushing en bij patiënten met 
acromegalie vergeleken met de mortaliteit bij patiënten met een NFMA. Bij deze laatste 
patiëntengroep ontbreken ziektespecifieke condities van zowel acromegalie alsook de 
ziekte van Cushing. 
De verhoogde mortaliteit bij patiënten met hypofysetumoren is geassocieerd met ver-
schillende factoren, waarvan sommige ziektespecifiek zijn. Transsfenoidale chirurgie gaat 
gepaard met een peri-operatieve mortaliteit van ~ 0.9% (80;81). Hypopituitarisme, aanwe-
zig bij het merendeel van de patiënten met een macroadenoom, is geassocieerd met een 
verhoogde mortaliteit (51;52). Verschillende studies rapporteren een verhoogde cerebro-, 
en cardiovasculaire sterfte bij patiënten met hypofysetumoren, anders dan de ziekte van 
Cushing en acromegalie (50;52;77-79). Hoewel de exacte mechanismen waardoor hypop-
itiuitarisme een verhoogde mortaliteit veroorzaakt niet duidelijk zijn, zijn er suggesties 
dat hypopituitarisme geassocieerd is met een verhoogd vasculair risicoprofiel (50;82-84). 
Verschillende auteurs wijzen in dit verband op de rol van onbehandelde groeihormoon 
deficiëntie (50;85). 
Cortisol excess induceert centrale obesitas, diabetes mellitus en hypertensie (86). Deze 
effecten zijn reversibel na curatie van de ziekte. Desondanks lijkt het zo te zijn dat cor-
tisol overproductie geassocieerd is met een verhoogd cardiovasculair risico, een risico dat 
mogelijk verhoogd blijft ook als de ziekte in remissie is (87;88). De effecten van cortisol 
overproductie zijn dus niet compleet reversibel en kunnen daarmee van invloed zijn op 
de mortaliteit. 
De mortaliteit van het gehele cohort was 41% hoger dan in de algemene bevolking, 
ondanks adequate behandeling (hoofdstuk 5). Daarnaast vonden we dat de mortaliteits-
cijfers verschillend waren voor de 3 hypofyse ziekten. De gestandaardiseerde mortaliteit 
ratio (SMR) bij patiënten met een NFMA was 1.24 (95% CI 0.82-1.74). Bij patiënten met de 
ziekte van Cushing was de SMR 2.39 (95% CI 1.22-3.9). Daarnaast was er een verhoogd 
relatief mortaliteitsrisico (2.3) bij patiënten met de ziekte van Cushing in vergelijking met 
NFMA patiënten. Dit wijst op de rol van cortisol bij de verhoogde mortaliteit, te meer 
daar de medische behandeling van de Cushing en de NFMA groep vergelijkbaar was. 
Het belang van cortisol wordt onderstreept door het feit dat patiënten met persisterende 
ziekte van Cushing een hogere mortaliteit hebben dan gecureerde patiënten (89;90). 
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Klinische implicaties. Het relatieve mortaliteitsrisico is verhoogd bij patinten met de 
ziekte van Cushing in vergelijking met de NFMA alsook met acromegalie patiënten. Dit 
impliceert dat cortisol-overproductie een essentiële bijdrage vormt voor de toegenomen 
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